# EDGAR Filing Document

**Accession Number:** 0001653477
**File Stem:** 0001653477-25-000133
**Filing Date:** 2025-12
**Character Count:** 103075
**Document Hash:** 3527a95dca6205a65e774c1a57d48f8d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001653477-25-000133.hdr.sgml**: 20251201

**ACCESSION NUMBER**: 0001653477-25-000133

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251201

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251201

**DATE AS OF CHANGE**: 20251201

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ingevity Corp
- **CENTRAL INDEX KEY:** 0001653477
- **STANDARD INDUSTRIAL CLASSIFICATION:** CHEMICALS & ALLIED PRODUCTS [2800]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 474027764
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37586
- **FILM NUMBER:** 251540444

**BUSINESS ADDRESS:**
- **STREET 1:** 4920 O'HEAR AVENUE
- **STREET 2:** SUITE 400
- **CITY:** NORTH CHARLESTON
- **STATE:** SC
- **ZIP:** 29405
- **BUSINESS PHONE:** 8437402300

**MAIL ADDRESS:**
- **STREET 1:** 4920 O'HEAR AVENUE
- **STREET 2:** SUITE 400
- **CITY:** NORTH CHARLESTON
- **STATE:** SC
- **ZIP:** 29405

?xml version='1.0' encoding='ASCII'? ngvt-20251201

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

_______________________________________________________________________

**FORM 8-K** 

_______________________________________________________________________

**CURRENT REPORT**

**Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934**

**December 1, 2025** 

**Date of Report (date of earliest event reported)**

__________________________________________________________________________

![ingevitylogorgba11.jpg](ngvt-20251201_g1.jpg)

**INGEVITY CORPORATION**

**(Exact name of registrant as specified in its charter)**

__________________________________________________________________________

---

| | | | |
|:---|:---|:---|:---|
| **Delaware** | **Delaware** | **001-37586** | **47-4027764** |
| (State or other jurisdiction of incorporation or organization) | (State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) |
| **4920 O'Hear Avenue Suite 400** | **North Charleston** | **South Carolina** | **29405** |
| (Address of principal executive offices) | (Address of principal executive offices) | (Address of principal executive offices) | (Zip code) |

---

**Registrant's telephone number, including area code: 843-740-2300** 

**Not Applicable**

**(Former name or former address, if changed since last report)**

_____________________________________________________________________________________________________

---

| | |
|:---|:---|
| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: | Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

---

---

| | | |
|:---|:---|:---|
| Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| **Common Stock ($0.01 par value)** | **NGVT** | **New York Stock Exchange** |

---

---

| | | |
|:---|:---|:---|
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). |
| ☐ | Emerging growth company | |
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act | □ |

---

_____________________________________________________________________________________________________

------

**<u>ITEM 7.01. REGULATION FD DISCLOSURE</u>**

On September 3, 2025, Ingevity Corporation, a Delaware corporation ("Ingevity", "the Company") entered into an Asset Purchase Agreement (the "Purchase Agreement") with Mainstream Pine Products, LLC, a Delaware limited liability company ("Purchaser"), pursuant to which Purchaser will purchase substantially all of the assets and assume and acquire certain of the rights and liabilities of Ingevity or its applicable affiliates that relate to or are used in connection with (a) Ingevity's industrial specialties product line (other than Ingevity's lignin dispersant and alternative fatty acid based products, road technologies product line and other businesses and products more fully described in the Purchase Agreement) and (b) Ingevity's North Charleston, South Carolina crude tall oil refinery (the "CTO Refinery") and Ingevity's and its affiliates' operations thereof (collectively, the "Divestiture"). The Divestiture is expected to close by early 2026.

Ingevity previously disclosed the Divestiture and the Asset Purchase Agreement (the "Purchase Agreement") in a Current Report on Form 8-K filed by Ingevity with the Securities and Exchange Commission (the "SEC") on September 3, 2025 (the "Previous Form 8-K"). The foregoing description of the Purchase Agreement and the acquisition does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Purchase Agreement filed as Exhibit 2.1 to the Previous Form 8-K, which is incorporated herein by reference.

In connection with the transaction, the Company determined that the industrial specialties product line and CTO Refinery included within the Divestiture met the criteria to be classified as held for sale and that the sale represents a strategic shift that will have a major effect on Ingevity's operations and results. Accordingly, for all periods presented, the results of operations of the industrial specialties product line and CTO Refinery, collectively defined above as the Divestiture, are presented as discontinued operations within this Form 8-K.

Ingevity is providing, attached as Exhibit 99.1, unaudited recast Condensed Consolidated Statements of Operations, Segment Operating Results, and certain Non-GAAP Financial Measures for the years ended December 31, 2024 and 2023 as well as the three month periods ended March 31, 2025 and 2024, June 30, 2025 and 2024, September 30, 2025 and 2024, and December 31, 2024, that reflect the industrial specialties product line and the CTO Refinery as discontinued operations. These reporting changes have been retrospectively applied for all periods presented. These amounts are considered preliminary, and as such, actual amounts could differ from these estimates.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

**<u>ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS</u>**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description of Exhibit** |
| <u>[2.1](https://www.sec.gov/Archives/edgar/data/1653477/000149315225012603/ex2-1.htm)</u> | Asset Purchase Agreement, dated September 3, 2025, by and between Ingevity Corporation and Mainstream Pine Products, LLC (incorporated by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K, as filed with the U.S. Securities and Exchange Commission on September 4, 2025)\* |
| <u>[99.1](ex991discops.htm)</u> | Recast Condensed Consolidated Statement of Operations, Historical Segment Information and certain Non-GAAP Financial Measures Reflecting the Industrial Specialties product line and CTO Refinery as Discontinued Operations (Unaudited) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

\* Incorporated by reference.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **INGEVITY CORPORATION** | **INGEVITY CORPORATION** |
| **(Registrant)** | **(Registrant)** |
| By: | /S/ MARY DEAN HALL |
|  | **Mary Dean Hall** |
|  | **Executive Vice President and Chief Financial Officer** |

---

Date: December 1, 2025

## Exhibit 99.1

**Exhibit 99.1**

**INGEVITY CORPORATION**

**Recast Condensed Consolidated Statement of Operations, Historical Segment Information and certain Non-GAAP Financial Measures Excluding the Industrial Specialties product line and CTO Refinery (Discontinued Operations) (Unaudited)**

On September 3, 2025, Ingevity Corporation, a Delaware corporation ("Ingevity", "the Company") entered into an Asset Purchase Agreement (the "Purchase Agreement") with Mainstream Pine Products, LLC, a Delaware limited liability company ("Purchaser"), pursuant to which Purchaser will purchase substantially all of the assets and assume and acquire certain of the rights and liabilities of Ingevity or its applicable affiliates that relate to or are used in connection with (a) Ingevity's industrial specialties product line (other than Ingevity's lignin dispersant and alternative fatty acid based products, road technologies product line and other businesses and products more fully described in the Purchase Agreement) and (b) Ingevity's North Charleston, South Carolina crude tall oil refinery (the "CTO Refinery") and Ingevity's and its affiliates' operations thereof (collectively, the "Divestiture"). The Company has determined that the industrial specialties product line and CTO Refinery included within the Divestiture met the criteria to be classified as held for sale and that the sale represents a strategic shift that will have a major effect on Ingevity's operations and results. Accordingly, for all periods presented, the results of operations of the industrial specialties product line and CTO Refinery, collectively defined above as the Divestiture, are presented as discontinued operations. The Divestiture is expected to close by early 2026.

Ingevity is providing, within this exhibit, unaudited recast Condensed Consolidated Statements of Operations, Segment Operating Results, and certain Non-GAAP Financial Measures for the years ended December 31, 2024 and 2023 as well as the three month periods ended March 31, 2025 and 2024, June 30, 2025 and 2024, September 30, 2025 and 2024, and December 31, 2024, that reflect the industrial specialties product line and the CTO Refinery as discontinued operations. These reporting changes have been retrospectively applied for all periods presented. These amounts are considered preliminary, and as such, actual amounts could differ from these estimates.

**Non-GAAP Financial Measures**

Ingevity has presented certain financial measures, defined below, which have not been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") and has provided a reconciliation to the most directly comparable financial measure calculated in accordance with GAAP on the following pages. These financial measures are not meant to be considered in isolation nor as a substitute for the most directly comparable financial measure calculated in accordance with GAAP. Investors should consider the limitations associated with these non-GAAP measures, including the potential lack of comparability of these measures from one company to another.

We believe these non-GAAP financial measures provide management as well as investors, potential investors, securities analysts, and others with useful information to evaluate the performance of the business, because such measures, when viewed together with our financial results computed in accordance with GAAP, provide a more complete understanding of the factors and trends affecting our historical financial performance, liquidity measures, and projected future results.

**Adjusted earnings (loss) from continuing operations** is defined as net income (loss) from continuing operations plus restructuring and other (income) charges, net, goodwill impairment charges, acquisition and other-related (income) costs, pension and postretirement settlement and curtailment (income) charges, (gain) loss on strategic investments, debt refinancing fees, litigation verdict charges, proxy contest charges, portfolio review expenses, and the income tax expense (benefit) on those items, less the provision (benefit) from certain discrete tax items.

**Adjusted earnings (loss) from discontinued operations** is defined as net income (loss) from discontinued operations plus restructuring and other (income) charges, net, goodwill impairment charges, acquisition and other-related (income) costs, loss on CTO resales, CTO supply contract termination charges, (gain) loss on strategic investments, and the income tax expense (benefit) on those items, less the provision (benefit) from certain discrete tax items.

**Total adjusted earnings (loss)** is defined as Adjusted earnings (loss) from continuing operations and Adjusted earnings (loss) from discontinued operations.

**Diluted adjusted earnings (loss) from continuing operations per share** is defined as diluted earnings (loss) from continuing operations per share plus restructuring and other (income) charges, net, per share, goodwill impairment charges per share, acquisition and other-related (income) costs per share, pension and postretirement settlement and curtailment (income) charges per share, (gain) loss on strategic investments per share, debt refinancing fees per share, litigation verdict charge per share, proxy contest charges per share, portfolio review expenses per share, and the income tax expense (benefit) per share on those items, less the provision (benefit) from certain discrete tax items per share.

------

**Diluted adjusted earnings (loss) from discontinued operations per share** is defined as diluted earnings (loss) from discontinued operations per share plus restructuring and other (income) charges, net, per share, goodwill impairment charges per share, acquisition and other-related (income) costs per share, loss on CTO resales per share, CTO supply contract termination charges per share, (gain) loss on strategic investments per share, and the income tax expense (benefit) per share on those items, less the provision (benefit) from certain discrete tax items per share.

**Total diluted adjusted earnings (loss) per share** is defined as diluted adjusted earnings (loss) from continuing operations per share and diluted adjusted earnings (loss) from discontinued operations per share.

**Adjusted EBITDA from continuing operations** is defined as net income (loss) from continuing operations plus interest expense, net, provision (benefit) for income taxes, depreciation, amortization, restructuring and other (income) charges, net, goodwill impairment charges, acquisition and other-related (income) costs, litigation verdict charges, (gain) loss on strategic investments, proxy contest charges, portfolio review expenses, and pension and postretirement settlement and curtailment (income) charges, net.

**Adjusted EBITDA margin from continuing operations** is defined as Adjusted EBITDA from continuing operations divided by Net sales from continuing operations

**Adjusted EBITDA from discontinued operations** is defined as net income (loss) from discontinued operations plus interest expense, net, provision (benefit) for income taxes, depreciation, amortization, restructuring and other (income) charges, net, goodwill impairment charges, acquisition and other-related (income) costs, (gain) loss on strategic investments, loss on CTO resales, and CTO supply contract termination charges.

**Total adjusted EBITDA** is defined as Adjusted EBITDA from continuing operations and Adjusted EBITDA from discontinued operations.

**Net Debt** is defined as the sum of notes payable, short-term debt, current maturities of long-term debt and long-term debt including finance lease obligations less the sum of cash and cash equivalents, restricted cash associated with our new market tax credit financing arrangement, and restricted investment associated with certain finance lease obligations, excluding the allowance for credit losses on held-to-maturity debt securities held within the restricted investment.

**Net Debt Ratio** is defined as Net Debt divided by the last twelve months Total Adjusted EBITDA.

Ingevity's management also uses the above financial measures as the primary measures of profitability and liquidity of the business. In addition, Ingevity believes Adjusted EBITDA from continuing operations and Adjusted EBITDA Margin from continuing operations are useful measures because they exclude the effects of financing and investment activities as well as non-operating activities.

**Forward-looking statements:** This Current Report on Form 8-K contains "forward looking statements" within the meaning of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Such statements generally include the words "will," "plans," "intends," "targets," "expects," "outlook," "guidance," "believes," "anticipates" or similar expressions. Forward looking statements may include, without limitation, anticipated timing, results, charges and costs of any current or future repositioning of our Performance Chemicals segment, including the Divestiture, the oleo-based product refining transition, closure of our plants in Crossett, Arkansas and DeRidder, Louisiana, the timing and closing of the Divestiture, the potential benefits of any divestiture, acquisition or investment transaction, including the Divestiture and payment of any contingent consideration pursuant thereto, leadership transitions within our organization, expected financial positions, guidance, results of operations and cash flows; financing plans; business strategies and expectations; operating plans; capital and other expenditures; competitive positions; growth opportunities for existing products; benefits from new technology and cost reduction initiatives, plans and objectives; litigation-related strategies and outcomes; and markets for securities. Actual results could differ materially from the views expressed. Factors that could cause actual results to materially differ from those contained in the forward looking statements, or that could cause other forward looking statements to prove incorrect, include, without limitation, risks related to the satisfaction of the conditions to closing the Divestiture in the anticipated timeframe or at all; risks that the expected benefits from the Divestiture will not be realized or will not be realized within the expected time period; the risks that associated with the co-located businesses and potential impacts to our plant operations, charges, costs or actions, including adverse legal or regulatory actions, resulting from, or in connection with, the current or future repositioning of our Performance Chemicals segment, including the Divestiture, the oleo-based product refining transition, closure of our plants in Crossett, Arkansas and DeRidder, Louisiana; losses due to resale of crude tall oil at less than we paid for it; leadership transitions

------

within our organization; adverse effects from general global economic, geopolitical and financial conditions beyond our control, including inflation, global trade tensions, and the Russia Ukraine war and conflict in the middle east; risks related to our international sales and operations, including changes in tariffs; adverse conditions in the automotive market; competition from substitute products, new technologies and new or emerging competitors; worldwide air quality standards; a decrease in government infrastructure spending; adverse conditions in cyclical end markets; the limited supply of or lack of access to sufficient raw materials, or any material increase in the cost to acquire such raw materials; issues with or integration of future acquisitions and other investments; the provision of services by third parties at several facilities; supply chain disruptions; natural disasters and extreme weather events; or other unanticipated problems such as labor difficulties (including work stoppages), equipment failure or unscheduled maintenance and repair; planned and unplanned production slowdowns and shutdowns, turnarounds and outages, attracting and retaining key personnel; dependence on certain large customers; legal actions associated with our intellectual property rights; protection of our intellectual property and other proprietary information; information technology security breaches and other disruptions; complications with designing or implementing our new enterprise resource planning system; government policies and regulations, including, but not limited to, those affecting the environment, climate change, tax policies, tariffs and the chemicals industry; losses due to lawsuits arising out of environmental damage or personal injuries associated with chemical or other manufacturing processes; and the other factors detailed from time to time in the reports we file with the Securities and Exchange Commission (the "SEC"), including those described in Part I, Item 1A. Risk Factors in our most recent Annual Report on Form 10 K as well as in our other filings with the SEC. These forward-looking statements speak only to management's beliefs as of the date of this Current Report on Form 8-K. Ingevity assumes no obligation to provide any revisions to, or update, any projections and forward-looking statements contained in this Current Report on Form 8-K.

------

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| **FINANCIAL SCHEDULES** | **FINANCIAL SCHEDULES** |
| | **Page** |
| <u>[Summary of Certain](#i93d0f3d7cd8f497ca0ad72edf1650836_2748779070010)[Recast](#i93d0f3d7cd8f497ca0ad72edf1650836_2748779070010)[Financial Measures](#i93d0f3d7cd8f497ca0ad72edf1650836_2748779070010)</u> | <u>[4](#i93d0f3d7cd8f497ca0ad72edf1650836_2748779070010)</u> |
| <u>[Recast](#i93d0f3d7cd8f497ca0ad72edf1650836_552)[Condensed Consolidated Statement of Operations](#i93d0f3d7cd8f497ca0ad72edf1650836_552)</u> | <u>[5](#i93d0f3d7cd8f497ca0ad72edf1650836_552)</u> |
| <u>[Recast](#i93d0f3d7cd8f497ca0ad72edf1650836_2748779069712)[Segment Operating Results and Disclosures](#i93d0f3d7cd8f497ca0ad72edf1650836_2748779069712)</u> | <u>[6](#i93d0f3d7cd8f497ca0ad72edf1650836_2748779069712)</u> |
| <u>[Detailed Reconciliations](#i93d0f3d7cd8f497ca0ad72edf1650836_504)</u> |  |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[Recast](#i93d0f3d7cd8f497ca0ad72edf1650836_1649267441834)[Reconciliation of Segment Operating Results](#i93d0f3d7cd8f497ca0ad72edf1650836_1649267441834)</u> | <u>[9](#i93d0f3d7cd8f497ca0ad72edf1650836_1649267441834)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[Recast Reconciliation of Adjusted Earnings (Loss) from continuing operations and Diluted Adjusted Earnings (loss) per Share from continuing operations](#i93d0f3d7cd8f497ca0ad72edf1650836_1649267441967)</u> | <u>[18](#i93d0f3d7cd8f497ca0ad72edf1650836_1649267441967)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[Recast Reconciliation of Adjusted EBITDA from continuing operations](#i93d0f3d7cd8f497ca0ad72edf1650836_355)</u> | <u>[29](#i93d0f3d7cd8f497ca0ad72edf1650836_355)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[Net Debt Ratio](#i93d0f3d7cd8f497ca0ad72edf1650836_405)</u> | <u>[30](#i93d0f3d7cd8f497ca0ad72edf1650836_405)</u> |

---

------

**INGEVITY CORPORATION**

**Summary of Certain Financial Measures from Continuing Operations (Unaudited)**

**Background:**

Below includes an excerpt of certain key financial measures that have been recast to exclude the Performance Chemicals industrial specialties product line and the CTO Refinery, which are considered discontinued operations. Detailed reconciliations of these key financial measures are included on the following pages within this Exhibit.

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **2023** | **2024** | **2024** | **2024** | **2024** | **2024** | **2025** | **2025** | **2025** |
| ***In millions, except per share data and net debt ratio*** | **FY** | **Q1** | **Q2** | **Q3** | **Q4** | **FY** | **Q1** | **Q2** | **Q3** |
| **Total Ingevity** |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net sales from continuing operations | $1215.5 | $255.2 | $347.7 | $333.8 | $263.4 | $1200.1 | $247.9 | $331.5 | $333.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) from continuing operations | $105.8 | $23.2 | $(211.6) | $47.5 | $19.5 | $(121.4) | $29.1 | $(141.4) | $40.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net Income Margin from continuing operations | 8.7% | 9.1% | (60.9)% | 14.2% | 7.4% | (10.1)% | 11.7% | (42.7)% | 12.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted earnings (loss) per share from continuing operations | $2.88 | $0.64 | $(5.83) | $1.30 | $0.53 | $(3.34) | $0.79 | $(3.87) | $1.10 |
| **Performance Chemicals (ex. Divestiture)** |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net sales | $425.5 | $62.1 | $142.6 | $133.9 | $63.3 | $401.9 | $58.9 | $134.3 | $139.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Segment EBITDA | $62.5 | $(2.1) | $23 | $24.3 | $1.3 | $46.5 | $3.6 | $26.7 | $24.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Segment EBITDA as a Percentage of Net sales | 14.7% | (3.4)% | 16.1% | 18.1% | 2.1% | 11.6% | 6.1% | 19.9% | 17.7% |
| **Non-GAAP Financial Measures** <sup>(1)</sup> |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Adjusted EBITDA from continuing operations | $353 | $79.2 | $109 | $108.4 | $79.9 | $376.5 | $91.3 | $101 | $110.4 |
| &nbsp;&nbsp;&nbsp;Adjusted EBITDA Margin from continuing operations | 29.0% | 31.0% | 31.3% | 32.5% | 30.3% | 31.4% | 36.8% | 30.5% | 33.1% |
| &nbsp;&nbsp;&nbsp;Adjusted earnings (loss) from continuing operations | $134.8 | $25.2 | $49.2 | $48.5 | $25.4 | $148.3 | $37 | $44.9 | $48.3 |
| &nbsp;&nbsp;&nbsp;Diluted Adjusted Earnings per Share from continuing operations | $3.67 | $0.69 | $1.35 | $1.33 | $0.69 | $4.06 | $1.01 | $1.22 | $1.31 |
| &nbsp;&nbsp;&nbsp;Net Debt Ratio | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4x | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.8x | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.0x | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.0x | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.5x | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.5x | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3x | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.0x | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.7x |
| _______________ | _______________ | _______________ | _______________ | _______________ | _______________ | _______________ | _______________ | _______________ | _______________ |
| (1) These are non-GAAP financial measures; please see subsequent pages for the reconciliations to the nearest GAAP financial measures. | (1) These are non-GAAP financial measures; please see subsequent pages for the reconciliations to the nearest GAAP financial measures. | (1) These are non-GAAP financial measures; please see subsequent pages for the reconciliations to the nearest GAAP financial measures. | (1) These are non-GAAP financial measures; please see subsequent pages for the reconciliations to the nearest GAAP financial measures. | (1) These are non-GAAP financial measures; please see subsequent pages for the reconciliations to the nearest GAAP financial measures. | (1) These are non-GAAP financial measures; please see subsequent pages for the reconciliations to the nearest GAAP financial measures. | (1) These are non-GAAP financial measures; please see subsequent pages for the reconciliations to the nearest GAAP financial measures. | (1) These are non-GAAP financial measures; please see subsequent pages for the reconciliations to the nearest GAAP financial measures. | (1) These are non-GAAP financial measures; please see subsequent pages for the reconciliations to the nearest GAAP financial measures. | (1) These are non-GAAP financial measures; please see subsequent pages for the reconciliations to the nearest GAAP financial measures. |

---

------

**INGEVITY CORPORATION**

**Recast Condensed Consolidated Statements of Operations from Continuing Operations (Unaudited)**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **2023** | **2024** | **2024** | **2024** | **2024** | **2024** | **2025** | **2025** | **2025** |
| ***In millions, except per share data*** | **FY** | **Q1** | **Q2** | **Q3** | **Q4** | **FY** | **Q1** | **Q2** | **Q3** |
| Net sales | $1215.5 | $255.2 | $347.7 | $333.8 | $263.4 | $1200.1 | $247.9 | $331.5 | $333.1 |
| Cost of sales | 770.5 | 150.4 | 219.3 | 202.2 | 163.4 | 735.3 | 136.0 | 203.7 | 199.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross profit | $445.0 | $104.8 | $128.4 | $131.6 | $100.0 | $464.8 | $111.9 | $127.8 | $133.9 |
| Selling, general, and administrative expenses | 161.8 | 43.3 | 38.3 | 37.9 | 38.3 | 157.8 | 41.9 | 43.6 | 44.1 |
| Research and technical expenses | 25.4 | 5.8 | 5.9 | 6.2 | 6.6 | 24.5 | 7.0 | 7.0 | 7.0 |
| Restructuring and other (income) charges, net | 53.4 | 1.3 | 3.7 | 3.3 | 9.8 | 18.1 | 1.9 | 7.2 | 1.0 |
| Goodwill impairment charge |  |  | 306.6 |  |  | 306.6 |  | 183.8 |  |
| Acquisition-related costs | 3.6 | 0.3 | (0.2) | (0.1) | 0.3 | 0.3 |  |  |  |
| Other (income) expense, net | (16.2) | 0.9 | 0.4 | 6.5 | 0.1 | 7.9 | 4.1 | 4.2 | 1.2 |
| Interest expense, net | 87.0 | 22.3 | 23.2 | 23.8 | 20.8 | 90.1 | 19.4 | 18.6 | 18.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income (loss) from continuing operations before income taxes | $130 | $30.9 | $(249.5) | $54 | $24.1 | $(140.5) | $37.6 | $(136.6) | $62.2 |
| Provision (benefit) for income taxes on continuing operations | 24.2 | 7.7 | (37.9) | 6.5 | 4.6 | (19.1) | 8.5 | 4.8 | 21.4 |
| &nbsp;&nbsp;Net income (loss) from continuing operations | $105.8 | $23.2 | $(211.6) | $47.5 | $19.5 | $(121.4) | $29.1 | $(141.4) | $40.8 |
| Per share data |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Basic earnings (loss) per share from continuing operations | $2.90 | $0.64 | $(5.83) | $1.31 | $0.54 | $(3.34) | $0.80 | $(3.87) | $1.12 |
| &nbsp;&nbsp;Diluted earnings (loss) per share from continuing operations | $2.88 | $0.64 | $(5.83) | $1.30 | $0.53 | $(3.34) | $0.79 | $(3.87) | $1.10 |
| Weighted average shares outstanding |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Basic | 36.5 | 36.3 | 36.3 | 36.3 | 36.3 | 36.3 | 36.4 | 36.5 | 36.3 |
| &nbsp;&nbsp;Diluted | 36.7 | 36.4 | 36.3 | 36.5 | 36.6 | 36.3 | 36.7 | 36.5 | 37.0 |

---

------

**INGEVITY CORPORATION**

**Recast Segment Operating Results from Continuing Operations (Unaudited)**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **2023** | **2024** | **2024** | **2024** | **2024** | **2024** | **2025** | **2025** | **2025** |
| ***In millions, except per share data*** | **FY** | **Q1** | **Q2** | **Q3** | **Q4** | **FY** | **Q1** | **Q2** | **Q3** |
| Performance Materials  | $586.0 | $145.1 | $157.2 | $151.1 | $156.2 | $609.6 | $146.8 | $153.9 | $155.0 |
| Performance Chemicals (ex. Divestiture) | 425.5 | 62.1 | 142.6 | 133.9 | 63.3 | 401.9 | 58.9 | 134.3 | 139.9 |
| Advanced Polymer Technologies | 204.0 | 48.0 | 47.9 | 48.8 | 43.9 | 188.6 | 42.2 | 43.3 | 38.2 |
| &nbsp;&nbsp;&nbsp;Net sales | $1215.5 | $255.2 | $347.7 | $333.8 | $263.4 | $1200.1 | $247.9 | $331.5 | $333.1 |
| Performance Materials | $286.6 | $78.0 | $82.2 | $80.6 | $78.3 | $319.1 | $79.1 | $77.1 | $79.9 |
| Performance Chemicals (ex. Divestiture) | 62.5 | (2.1) | 23.0 | 24.3 | 1.3 | 46.5 | 3.6 | 26.7 | 24.8 |
| Advanced Polymer Technologies | 44.5 | 9.5 | 9.8 | 9.8 | 6.1 | 35.2 | 12.5 | 0.9 | 9.9 |
| &nbsp;&nbsp;Segment EBITDA  | $393.6 | $85.4 | $115.0 | $114.7 | $85.7 | $400.8 | $95.2 | $104.7 | $114.6 |
| &nbsp;&nbsp;Interest expense, net | (87.0) | (22.3) | (23.2) | (23.8) | (20.8) | (90.1) | (19.4) | (18.6) | (18.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;(Provision) benefit for income taxes | (24.2) | (7.7) | 37.9 | (6.5) | (4.6) | 19.1 | (8.5) | (4.8) | (21.4) |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | (97.4) | (24.4) | (25.3) | (25.2) | (24.7) | (99.6) | (24.5) | (25.2) | (27.7) |
| &nbsp;&nbsp;&nbsp;Restructuring and other income (charges), net | (53.4) | (1.3) | (3.7) | (3.3) | (9.8) | (18.1) | (1.9) | (7.2) | (1.0) |
| &nbsp;&nbsp;&nbsp;Goodwill impairment charge |  |  | (306.6) |  |  | (306.6) |  | (183.8) |  |
| &nbsp;&nbsp;&nbsp;Acquisition and other-related costs | (4.5) | (0.3) | 0.2 | 0.1 | (0.3) | (0.3) |  |  |  |
| &nbsp;&nbsp;&nbsp;Pension and postretirement settlement and curtailment (charges) income, net |  |  |  |  | (0.2) | (0.2) |  |  |  |
| &nbsp;&nbsp;&nbsp;Gain (loss) on strategic investments | 19.3 |  | 0.1 | (2.2) |  | (2.1) |  | (2.5) |  |
| &nbsp;&nbsp;&nbsp;Proxy contest charges |  |  |  |  |  |  | (7.9) | (0.3) |  |
| &nbsp;&nbsp;&nbsp;Portfolio review expenses |  |  |  |  |  |  |  |  | (1.1) |
| &nbsp;&nbsp;Indirect costs allocated to Divestiture <sup>(1)</sup> | (40.6) | (6.2) | (6.0) | (6.3) | (5.8) | (24.3) | (3.9) | (3.7) | (4.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) from continuing operations | $105.8 | $23.2 | $(211.6) | $47.5 | $19.5 | $(121.4) | $29.1 | $(141.4) | $40.8 |
| _______________ |  |  |  |  |  |  |  |  |  |
| (1) Includes indirect costs previously allocated to the Divestiture that are not eligible for discontinued operations accounting treatment.  | (1) Includes indirect costs previously allocated to the Divestiture that are not eligible for discontinued operations accounting treatment.  | (1) Includes indirect costs previously allocated to the Divestiture that are not eligible for discontinued operations accounting treatment.  | (1) Includes indirect costs previously allocated to the Divestiture that are not eligible for discontinued operations accounting treatment.  | (1) Includes indirect costs previously allocated to the Divestiture that are not eligible for discontinued operations accounting treatment.  | (1) Includes indirect costs previously allocated to the Divestiture that are not eligible for discontinued operations accounting treatment.  | (1) Includes indirect costs previously allocated to the Divestiture that are not eligible for discontinued operations accounting treatment.  | (1) Includes indirect costs previously allocated to the Divestiture that are not eligible for discontinued operations accounting treatment.  | (1) Includes indirect costs previously allocated to the Divestiture that are not eligible for discontinued operations accounting treatment.  | (1) Includes indirect costs previously allocated to the Divestiture that are not eligible for discontinued operations accounting treatment.  |

---

------

**INGEVITY CORPORATION**

**Recast Segment Operating Disclosures from Continuing Operations (Unaudited)**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Performance Materials** | **Performance Materials** | **Performance Materials** | **Performance Materials** | **Performance Materials** | **Performance Materials** | **Performance Materials** | **Performance Materials** | **Performance Materials** |
| | **2023** | **2024** | **2024** | **2024** | **2024** | **2024** | **2025** | **2025** | **2025** |
| ***In millions*** | **FY** | **Q1** | **Q2** | **Q3** | **Q4** | **FY** | **Q1** | **Q2** | **Q3** |
| Net sales <sup>(i)</sup> | $586.0 | $145.1 | $157.2 | $151.1 | $156.2 | $609.6 | $146.8 | $153.9 | $155.0 |
| Less: |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Cost of sales <sup>(ii)</sup> | 254.2 | 52.1 | 61.4 | 56.4 | 64.0 | 233.9 | 54.4 | 58.8 | 58.9 |
| &nbsp;&nbsp;Selling, general, and administrative expenses <sup>(ii) (iii)</sup>  | 46.1 | 15.0 | 13.4 | 14.1 | 14.3 | 56.8 | 16.4 | 16.3 | 16.3 |
| &nbsp;&nbsp;Other (income) expense, net <sup>(ii) (iv)</sup> | (0.9) |  | 0.2 |  | (0.4) | (0.2) | (3.1) | 1.7 | (0.1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Segment EBITDA | $286.6 | $78.0 | $82.2 | $80.6 | $78.3 | $319.1 | $79.1 | $77.1 | $79.9 |

---

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Performance Chemicals (ex. Divestiture)** | **Performance Chemicals (ex. Divestiture)** | **Performance Chemicals (ex. Divestiture)** | **Performance Chemicals (ex. Divestiture)** | **Performance Chemicals (ex. Divestiture)** | **Performance Chemicals (ex. Divestiture)** | **Performance Chemicals (ex. Divestiture)** | **Performance Chemicals (ex. Divestiture)** | **Performance Chemicals (ex. Divestiture)** |
| | **2023** | **2024** | **2024** | **2024** | **2024** | **2024** | **2025** | **2025** | **2025** |
| ***In millions*** | **FY** | **Q1** | **Q2** | **Q3** | **Q4** | **FY** | **Q1** | **Q2** | **Q3** |
| Net sales <sup>(i)</sup> | $425.5 | $62.1 | $142.6 | $133.9 | $63.3 | $401.9 | $58.9 | $134.3 | $139.9 |
| Less: |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Cost of sales <sup>(ii)</sup> | 309.5 | 48.9 | 106.7 | 95.7 | 48.9 | 300.2 | 41.4 | 92.9 | 99.5 |
| &nbsp;&nbsp;Selling, general, and administrative expenses <sup>(ii) (iii)</sup>  | 53.4 | 14.8 | 12.7 | 11.6 | 12.3 | 51.4 | 14.6 | 14.8 | 15.4 |
| &nbsp;&nbsp;Other (income) expense, net <sup>(ii) (iv)</sup> | 0.1 | 0.5 | 0.2 | 2.3 | 0.8 | 3.8 | (0.7) | (0.1) | 0.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Segment EBITDA | $62.5 | $(2.1) | $23.0 | $24.3 | $1.3 | $46.5 | $3.6 | $26.7 | $24.8 |

---

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Advanced Polymer Technologies** | **Advanced Polymer Technologies** | **Advanced Polymer Technologies** | **Advanced Polymer Technologies** | **Advanced Polymer Technologies** | **Advanced Polymer Technologies** | **Advanced Polymer Technologies** | **Advanced Polymer Technologies** | **Advanced Polymer Technologies** |
| | **2023** | **2024** | **2024** | **2024** | **2024** | **2024** | **2025** | **2025** | **2025** |
| ***In millions*** | **FY** | **Q1** | **Q2** | **Q3** | **Q4** | **FY** | **Q1** | **Q2** | **Q3** |
| Net sales <sup>(i)</sup> | $204.0 | $48.0 | $47.9 | $48.8 | $43.9 | $188.6 | $42.2 | $43.3 | $38.2 |
| Less: |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Cost of sales <sup>(ii)</sup> | 135.2 | 32.4 | 32.4 | 32.2 | 32.9 | 129.9 | 23.6 | 35.7 | 22.1 |
| &nbsp;&nbsp;Selling, general, and administrative expenses <sup>(ii) (iii)</sup>  | 22.1 | 5.8 | 5.6 | 5.4 | 5.5 | 22.3 | 5.9 | 6.8 | 6.4 |
| &nbsp;&nbsp;Other (income) expense, net <sup>(ii) (iv)</sup> | 2.2 | 0.3 | 0.1 | 1.4 | (0.6) | 1.2 | 0.2 | (0.1) | (0.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;Segment EBITDA | $44.5 | $9.5 | $9.8 | $9.8 | $6.1 | $35.2 | $12.5 | $0.9 | $9.9 |
| _______________ |  |  |  |  |  |  |  |  |  |
| (i) Relates to external customers only. | (i) Relates to external customers only. | (i) Relates to external customers only. | (i) Relates to external customers only. | (i) Relates to external customers only. | (i) Relates to external customers only. | (i) Relates to external customers only. | (i) Relates to external customers only. | (i) Relates to external customers only. | (i) Relates to external customers only. |
| (ii) Excludes Depreciation and amortization. | (ii) Excludes Depreciation and amortization. | (ii) Excludes Depreciation and amortization. | (ii) Excludes Depreciation and amortization. | (ii) Excludes Depreciation and amortization. | (ii) Excludes Depreciation and amortization. | (ii) Excludes Depreciation and amortization. | (ii) Excludes Depreciation and amortization. | (ii) Excludes Depreciation and amortization. | (ii) Excludes Depreciation and amortization. |
| (iii) Includes Research and technical expenses. | (iii) Includes Research and technical expenses. | (iii) Includes Research and technical expenses. | (iii) Includes Research and technical expenses. | (iii) Includes Research and technical expenses. | (iii) Includes Research and technical expenses. | (iii) Includes Research and technical expenses. | (iii) Includes Research and technical expenses. | (iii) Includes Research and technical expenses. | (iii) Includes Research and technical expenses. |
| (iv) We have excluded the following items from Other (income) expense, net: gain (loss) on strategic investments, proxy contest charges, portfolio review expenses, pension and postretirement settlement and curtailment charges, depreciation, and amortization. | (iv) We have excluded the following items from Other (income) expense, net: gain (loss) on strategic investments, proxy contest charges, portfolio review expenses, pension and postretirement settlement and curtailment charges, depreciation, and amortization. | (iv) We have excluded the following items from Other (income) expense, net: gain (loss) on strategic investments, proxy contest charges, portfolio review expenses, pension and postretirement settlement and curtailment charges, depreciation, and amortization. | (iv) We have excluded the following items from Other (income) expense, net: gain (loss) on strategic investments, proxy contest charges, portfolio review expenses, pension and postretirement settlement and curtailment charges, depreciation, and amortization. | (iv) We have excluded the following items from Other (income) expense, net: gain (loss) on strategic investments, proxy contest charges, portfolio review expenses, pension and postretirement settlement and curtailment charges, depreciation, and amortization. | (iv) We have excluded the following items from Other (income) expense, net: gain (loss) on strategic investments, proxy contest charges, portfolio review expenses, pension and postretirement settlement and curtailment charges, depreciation, and amortization. | (iv) We have excluded the following items from Other (income) expense, net: gain (loss) on strategic investments, proxy contest charges, portfolio review expenses, pension and postretirement settlement and curtailment charges, depreciation, and amortization. | (iv) We have excluded the following items from Other (income) expense, net: gain (loss) on strategic investments, proxy contest charges, portfolio review expenses, pension and postretirement settlement and curtailment charges, depreciation, and amortization. | (iv) We have excluded the following items from Other (income) expense, net: gain (loss) on strategic investments, proxy contest charges, portfolio review expenses, pension and postretirement settlement and curtailment charges, depreciation, and amortization. | (iv) We have excluded the following items from Other (income) expense, net: gain (loss) on strategic investments, proxy contest charges, portfolio review expenses, pension and postretirement settlement and curtailment charges, depreciation, and amortization. |

---

**INGEVITY CORPORATION**

------

**Recast Segment Operating Disclosures from Continuing Operations (Unaudited)**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Depreciation and amortization** | **Depreciation and amortization** | **Depreciation and amortization** | **Depreciation and amortization** | **Depreciation and amortization** | **Depreciation and amortization** | **Depreciation and amortization** | **Depreciation and amortization** | **Depreciation and amortization** |
| | **2023** | **2024** | **2024** | **2024** | **2024** | **2024** | **2025** | **2025** | **2025** |
| ***In millions*** | **FY** | **Q1** | **Q2** | **Q3** | **Q4** | **FY** | **Q1** | **Q2** | **Q3** |
| Performance Materials | $38.3 | $9.6 | $9.7 | $9.7 | $9.7 | $38.7 | $9.9 | $9.9 | $11.3 |
| Performance Chemicals (ex. Divestiture) | 22.1 | 6.0 | 6.1 | 6.1 | 6.1 | 24.3 | 5.9 | 6.0 | 6.4 |
| Advanced Polymer Technologies | 31.3 | 7.6 | 7.5 | 7.9 | 7.8 | 30.8 | 7.7 | 8.3 | 8.9 |
| Indirect costs allocated to Divestiture <sup>(i)</sup> | 5.7 | 1.2 | 2.0 | 1.5 | 1.1 | 5.8 | 1.0 | 1.0 | 1.1 |
| &nbsp;&nbsp;Total Depreciation and amortization | $97.4 | $24.4 | $25.3 | $25.2 | $24.7 | $99.6 | $24.5 | $25.2 | $27.7 |
| _______________ | _______________ | _______________ | _______________ | _______________ | _______________ | _______________ | _______________ | _______________ | _______________ |
| (i) Includes indirect costs previously allocated to the Divestiture that are not eligible for discontinued operations accounting treatment.  | (i) Includes indirect costs previously allocated to the Divestiture that are not eligible for discontinued operations accounting treatment.  | (i) Includes indirect costs previously allocated to the Divestiture that are not eligible for discontinued operations accounting treatment.  | (i) Includes indirect costs previously allocated to the Divestiture that are not eligible for discontinued operations accounting treatment.  | (i) Includes indirect costs previously allocated to the Divestiture that are not eligible for discontinued operations accounting treatment.  | (i) Includes indirect costs previously allocated to the Divestiture that are not eligible for discontinued operations accounting treatment.  | (i) Includes indirect costs previously allocated to the Divestiture that are not eligible for discontinued operations accounting treatment.  | (i) Includes indirect costs previously allocated to the Divestiture that are not eligible for discontinued operations accounting treatment.  | (i) Includes indirect costs previously allocated to the Divestiture that are not eligible for discontinued operations accounting treatment.  | (i) Includes indirect costs previously allocated to the Divestiture that are not eligible for discontinued operations accounting treatment.  |
|  | **Capital expenditures** | **Capital expenditures** | **Capital expenditures** | **Capital expenditures** | **Capital expenditures** | **Capital expenditures** | **Capital expenditures** | **Capital expenditures** | **Capital expenditures** |
|  | **2023** | **2024** | **2024** | **2024** | **2024** | **2024** | **2025** | **2025** | **2025** |
| ***In millions*** | **FY** | **Q1** | **Q2** | **Q3** | **Q4** | **FY** | **Q1** | **Q2** | **Q3** |
| Performance Materials | $36.4 | $7.3 | $9.3 | $8.8 | $13.1 | $38.5 | $5.1 | $6.9 | $7.4 |
| Performance Chemicals (ex. Divestiture) | 29.2 | 3.2 | 3.7 | 4.9 | 4.7 | 16.5 | 1.2 | 1.5 | 2.8 |
| Advanced Polymer Technologies | 23.8 | 3.1 | 3.1 | 3.6 | 6.4 | 16.2 | 3.7 | 3.7 | 1.6 |
| &nbsp;&nbsp;Total Capital expenditures | $89.4 | $13.6 | $16.1 | $17.3 | $24.2 | $71.2 | $10.0 | $12.1 | $11.8 |

---

------

**INGEVITY CORPORATION**

**Reconciliation of Recast Segment Operating Results (Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **2025 Q3** | **2025 Q3** | **2025 Q3** | **2025 Q3** |
| ***In millions*** | **As Previously Reported** | **Indirect costs allocated to Divestiture** <sup>(1)</sup> | **Discontinued Operations** | **Continuing Operations** |
| Performance Materials  | $155.0 | $— | $— | $155.0 |
| Performance Chemicals | 168.9 |  | (29.0) | 139.9 |
| Advanced Polymer Technologies | 38.2 |  |  | 38.2 |
| &nbsp;&nbsp;&nbsp;**Net sales** | $362.1 | $— | $(29.0) | $333.1 |
| Performance Materials | $79.9 | $— | $— | $79.9 |
| Performance Chemicals | 31.4 | 4.2 | (10.8) | 24.8 |
| Advanced Polymer Technologies | 9.9 |  |  | 9.9 |
| &nbsp;&nbsp;**Segment EBITDA**  | $121.2 | $4.2 | $(10.8) | $114.6 |
| &nbsp;&nbsp;Interest expense, net | (18.4) |  |  | (18.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;(Provision) benefit for income taxes | (20.4) |  | (1.0) | (21.4) |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | (28.0) |  | 0.3 | (27.7) |
| &nbsp;&nbsp;&nbsp;Restructuring and other income (charges), net | (9.8) |  | 8.8 | (1.0) |
| &nbsp;&nbsp;&nbsp;Acquisition and other-related costs |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Portfolio review expenses | (1.1) |  |  | (1.1) |
| &nbsp;&nbsp;Indirect costs allocated to Divestiture <sup>(1)</sup> |  | (4.2) |  | (4.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net income (loss)** | $43.5 | $— | $(2.7) | $40.8 |

---

_____________

(1) Includes indirect costs previously allocated to the Divestiture that are not eligible for discontinued operations accounting treatment.

------

**INGEVITY CORPORATION**

**Reconciliation of Recast Segment Operating Results (Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **2025 Q2** | **2025 Q2** | **2025 Q2** | **2025 Q2** |
| ***In millions*** | **As Previously Reported** | **Indirect costs allocated to Divestiture** <sup>(1)</sup> | **Discontinued Operations** | **Continuing Operations** |
| Performance Materials  | $153.9 | $— | $— | $153.9 |
| Performance Chemicals | 167.9 |  | (33.6) | 134.3 |
| Advanced Polymer Technologies | 43.3 |  |  | 43.3 |
| &nbsp;&nbsp;&nbsp;**Net sales** | $365.1 | $— | $(33.6) | $331.5 |
| Performance Materials | $77.1 | $— | $— | $77.1 |
| Performance Chemicals | 32.0 | 3.7 | (9.0) | 26.7 |
| Advanced Polymer Technologies | 0.9 |  |  | 0.9 |
| &nbsp;&nbsp;**Segment EBITDA**  | $110.0 | $3.7 | $(9.0) | $104.7 |
| &nbsp;&nbsp;Interest expense, net | (18.6) |  |  | (18.6) |
| &nbsp;&nbsp;&nbsp;&nbsp;(Provision) benefit for income taxes | (3.8) |  | (1.0) | (4.8) |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | (25.6) |  | 0.4 | (25.2) |
| &nbsp;&nbsp;&nbsp;Restructuring and other income (charges), net | (21.9) |  | 14.7 | (7.2) |
| &nbsp;&nbsp;&nbsp;Goodwill impairment charge | (183.8) |  |  | (183.8) |
| &nbsp;&nbsp;&nbsp;Acquisition and other-related costs |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Gain (loss) on strategic investments | (2.5) |  |  | (2.5) |
| &nbsp;&nbsp;&nbsp;Proxy contest charges | (0.3) |  |  | (0.3) |
| &nbsp;&nbsp;Indirect costs allocated to Divestiture <sup>(1)</sup> |  | (3.7) |  | (3.7) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net income (loss)** | $(146.5) | $— | $5.1 | $(141.4) |

---

_____________

(1) Includes indirect costs previously allocated to the Divestiture that are not eligible for discontinued operations accounting treatment.

------

**INGEVITY CORPORATION**

**Reconciliation of Recast Segment Operating Results (Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **2025 Q1** | **2025 Q1** | **2025 Q1** | **2025 Q1** |
| ***In millions*** | **As Previously Reported** | **Indirect costs allocated to Divestiture** <sup>(1)</sup> | **Discontinued Operations** | **Continuing Operations** |
| Performance Materials  | $146.8 | $— | $— | $146.8 |
| Performance Chemicals | 95.0 |  | (36.1) | 58.9 |
| Advanced Polymer Technologies | 42.2 |  |  | 42.2 |
| &nbsp;&nbsp;&nbsp;**Net sales** | $284.0 | $— | $(36.1) | $247.9 |
| Performance Materials | $79.1 | $— | $— | $79.1 |
| Performance Chemicals | (0.3) | 3.9 |  | 3.6 |
| Advanced Polymer Technologies | 12.5 |  |  | 12.5 |
| &nbsp;&nbsp;**Segment EBITDA**  | $91.3 | $3.9 | $— | $95.2 |
| &nbsp;&nbsp;Interest expense, net | (19.4) |  |  | (19.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;(Provision) benefit for income taxes | (6.3) |  | (2.2) | (8.5) |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | (24.9) |  | 0.4 | (24.5) |
| &nbsp;&nbsp;&nbsp;Restructuring and other income (charges), net | (12.3) |  | 10.4 | (1.9) |
| &nbsp;&nbsp;&nbsp;Acquisition and other-related costs |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Proxy contest charges | (7.9) |  |  | (7.9) |
| &nbsp;&nbsp;Indirect costs allocated to Divestiture <sup>(1)</sup> |  | (3.9) |  | (3.9) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net income (loss)** | $20.5 | $— | $8.6 | $29.1 |

---

_____________

(1) Includes indirect costs previously allocated to the Divestiture that are not eligible for discontinued operations accounting treatment.

------

**INGEVITY CORPORATION**

**Reconciliation of Recast Segment Operating Results (Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **2024 FY** | **2024 FY** | **2024 FY** | **2024 FY** |
| ***In millions*** | **As Previously Reported** | **Indirect costs allocated to Divestiture** <sup>(1)</sup> | **Discontinued Operations** | **Continuing Operations** |
| Performance Materials  | $609.6 | $— | $— | $609.6 |
| Performance Chemicals | 608.2 |  | (206.3) | 401.9 |
| Advanced Polymer Technologies | 188.6 |  |  | 188.6 |
| &nbsp;&nbsp;&nbsp;**Net sales** | $1406.4 | $— | $(206.3) | $1200.1 |
| Performance Materials | $319.1 | $— | $— | $319.1 |
| Performance Chemicals | 14.7 | 24.3 | 7.5 | 46.5 |
| Advanced Polymer Technologies | 35.2 |  |  | 35.2 |
| &nbsp;&nbsp;**Segment EBITDA**  | $369.0 | $24.3 | $7.5 | $400.8 |
| &nbsp;&nbsp;Interest expense, net | (90.1) |  |  | (90.1) |
| &nbsp;&nbsp;&nbsp;&nbsp;(Provision) benefit for income taxes | 105.3 |  | (86.2) | 19.1 |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | (108.3) |  | 8.7 | (99.6) |
| &nbsp;&nbsp;&nbsp;Restructuring and other income (charges), net | (186.2) |  | 168.1 | (18.1) |
| &nbsp;&nbsp;&nbsp;Goodwill impairment charge | (349.1) |  | 42.5 | (306.6) |
| &nbsp;&nbsp;&nbsp;Acquisition and other-related costs | (0.3) |  |  | (0.3) |
| &nbsp;&nbsp;&nbsp;Inventory charges | (6.3) |  | 6.3 |  |
| &nbsp;&nbsp;&nbsp;Loss on CTO resales | (52.7) |  | 52.7 |  |
| &nbsp;&nbsp;&nbsp;CTO supply contract termination charges | (100.0) |  | 100.0 |  |
| &nbsp;&nbsp;&nbsp;Pension and postretirement settlement and curtailment (charges) income, net | (0.2) |  |  | (0.2) |
| &nbsp;&nbsp;&nbsp;Gain (loss) on strategic investments | (11.4) |  | 9.3 | (2.1) |
| &nbsp;&nbsp;Indirect costs allocated to Divestiture <sup>(1)</sup> |  | (24.3) |  | (24.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net income (loss)** | $(430.3) | $— | $308.9 | $(121.4) |

---

_____________

(1) Includes indirect costs previously allocated to the Divestiture that are not eligible for discontinued operations accounting treatment.

------

**INGEVITY CORPORATION**

**Reconciliation of Recast Segment Operating Results (Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **2024 Q4** | **2024 Q4** | **2024 Q4** | **2024 Q4** |
| ***In millions*** | **As Previously Reported** | **Indirect costs allocated to Divestiture** <sup>(1)</sup> | **Discontinued Operations** | **Continuing Operations** |
| Performance Materials  | $156.2 | $— | $— | $156.2 |
| Performance Chemicals | 98.7 |  | (35.4) | 63.3 |
| Advanced Polymer Technologies | 43.9 |  |  | 43.9 |
| &nbsp;&nbsp;&nbsp;**Net sales** | $298.8 | $— | $(35.4) | $263.4 |
| Performance Materials | $78.3 | $— | $— | $78.3 |
| Performance Chemicals | (3.8) | 5.8 | (0.7) | 1.3 |
| Advanced Polymer Technologies | 6.1 |  |  | 6.1 |
| &nbsp;&nbsp;**Segment EBITDA**  | $80.6 | $5.8 | $(0.7) | $85.7 |
| &nbsp;&nbsp;Interest expense, net | (20.8) |  |  | (20.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;(Provision) benefit for income taxes | 7.8 |  | (12.4) | (4.6) |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | (25.2) |  | 0.5 | (24.7) |
| &nbsp;&nbsp;&nbsp;Restructuring and other income (charges), net | (23.4) |  | 13.6 | (9.8) |
| &nbsp;&nbsp;&nbsp;Acquisition and other-related costs | (0.3) |  |  | (0.3) |
| &nbsp;&nbsp;&nbsp;Loss on CTO resales | (1.9) |  | 1.9 |  |
| &nbsp;&nbsp;&nbsp;Pension and postretirement settlement and curtailment (charges) income, net | (0.2) |  |  | (0.2) |
| &nbsp;&nbsp;Indirect costs allocated to Divestiture <sup>(1)</sup> |  | (5.8) |  | (5.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net income (loss)** | $16.6 | $— | $2.9 | $19.5 |

---

_____________

(1) Includes indirect costs previously allocated to the Divestiture that are not eligible for discontinued operations accounting treatment.

------

**INGEVITY CORPORATION**

**Reconciliation of Recast Segment Operating Results (Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **2024 Q3** | **2024 Q3** | **2024 Q3** | **2024 Q3** |
| ***In millions*** | **As Previously Reported** | **Indirect costs allocated to Divestiture** <sup>(1)</sup> | **Discontinued Operations** | **Continuing Operations** |
| Performance Materials  | $151.1 | $— | $— | $151.1 |
| Performance Chemicals | 177.0 |  | (43.1) | 133.9 |
| Advanced Polymer Technologies | 48.8 |  |  | 48.8 |
| &nbsp;&nbsp;&nbsp;**Net sales** | $376.9 | $— | $(43.1) | $333.8 |
| Performance Materials | $80.6 | $— | $— | $80.6 |
| Performance Chemicals | 19.8 | 6.3 | (1.8) | 24.3 |
| Advanced Polymer Technologies | 9.8 |  |  | 9.8 |
| &nbsp;&nbsp;**Segment EBITDA**  | $110.2 | $6.3 | $(1.8) | $114.7 |
| &nbsp;&nbsp;Interest expense, net | (23.8) |  |  | (23.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;(Provision) benefit for income taxes | 30.7 |  | (37.2) | (6.5) |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | (26.2) |  | 1.0 | (25.2) |
| &nbsp;&nbsp;&nbsp;Restructuring and other income (charges), net | (86.9) |  | 83.6 | (3.3) |
| &nbsp;&nbsp;&nbsp;Acquisition and other-related costs | 0.1 |  |  | 0.1 |
| &nbsp;&nbsp;&nbsp;Inventory charges | (3.8) |  | 3.8 |  |
| &nbsp;&nbsp;&nbsp;Loss on CTO resales | (0.8) |  | 0.8 |  |
| &nbsp;&nbsp;&nbsp;CTO supply contract termination charges | (100.0) |  | 100.0 |  |
| &nbsp;&nbsp;&nbsp;Gain (loss) on strategic investments | (6.7) |  | 4.5 | (2.2) |
| &nbsp;&nbsp;Indirect costs allocated to Divestiture <sup>(1)</sup> |  | (6.3) |  | (6.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net income (loss)** | $(107.2) | $— | $154.7 | $47.5 |

---

_____________

(1) Includes indirect costs previously allocated to the Divestiture that are not eligible for discontinued operations accounting treatment.

------

**INGEVITY CORPORATION**

**Reconciliation of Recast Segment Operating Results (Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **2024 Q2** | **2024 Q2** | **2024 Q2** | **2024 Q2** |
| ***In millions*** | **As Previously Reported** | **Indirect costs allocated to Divestiture** <sup>(1)</sup> | **Discontinued Operations** | **Continuing Operations** |
| Performance Materials  | $157.2 | $— | $— | $157.2 |
| Performance Chemicals | 185.5 |  | (42.9) | 142.6 |
| Advanced Polymer Technologies | 47.9 |  |  | 47.9 |
| &nbsp;&nbsp;&nbsp;**Net sales** | $390.6 | $— | $(42.9) | $347.7 |
| Performance Materials | $82.2 | $— | $— | $82.2 |
| Performance Chemicals | 9.3 | 6.0 | 7.7 | 23.0 |
| Advanced Polymer Technologies | 9.8 |  |  | 9.8 |
| &nbsp;&nbsp;**Segment EBITDA**  | $101.3 | $6.0 | $7.7 | $115.0 |
| &nbsp;&nbsp;Interest expense, net | (23.2) |  |  | (23.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;(Provision) benefit for income taxes | 50.9 |  | (13.0) | 37.9 |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | (27.3) |  | 2.0 | (25.3) |
| &nbsp;&nbsp;&nbsp;Restructuring and other income (charges), net | (13.1) |  | 9.4 | (3.7) |
| &nbsp;&nbsp;&nbsp;Goodwill impairment charge | (349.1) |  | 42.5 | (306.6) |
| &nbsp;&nbsp;&nbsp;Acquisition and other-related costs | 0.2 |  |  | 0.2 |
| &nbsp;&nbsp;&nbsp;Loss on CTO resales | (23.5) |  | 23.5 |  |
| &nbsp;&nbsp;&nbsp;Gain (loss) on strategic investments | 0.1 |  |  | 0.1 |
| &nbsp;&nbsp;Indirect costs allocated to Divestiture <sup>(1)</sup> |  | (6.0) |  | (6.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net income (loss)** | $(283.7) | $— | $72.1 | $(211.6) |

---

_____________

(1) Includes indirect costs previously allocated to the Divestiture that are not eligible for discontinued operations accounting treatment.

------

**INGEVITY CORPORATION**

**Reconciliation of Recast Segment Operating Results (Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **2024 Q1** | **2024 Q1** | **2024 Q1** | **2024 Q1** |
| ***In millions*** | **As Previously Reported** | **Indirect costs allocated to Divestiture** <sup>(1)</sup> | **Discontinued Operations** | **Continuing Operations** |
| Performance Materials  | $145.1 | $— | $— | $145.1 |
| Performance Chemicals | 147.0 |  | (84.9) | 62.1 |
| Advanced Polymer Technologies | 48.0 |  |  | 48.0 |
| &nbsp;&nbsp;&nbsp;**Net sales** | $340.1 | $— | $(84.9) | $255.2 |
| Performance Materials | $78.0 | $— | $— | $78.0 |
| Performance Chemicals | (10.6) | 6.2 | 2.3 | (2.1) |
| Advanced Polymer Technologies | 9.5 |  |  | 9.5 |
| &nbsp;&nbsp;**Segment EBITDA**  | $76.9 | $6.2 | $2.3 | $85.4 |
| &nbsp;&nbsp;Interest expense, net | (22.3) |  |  | (22.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;(Provision) benefit for income taxes | 15.9 |  | (23.6) | (7.7) |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | (29.6) |  | 5.2 | (24.4) |
| &nbsp;&nbsp;&nbsp;Restructuring and other income (charges), net | (62.8) |  | 61.5 | (1.3) |
| &nbsp;&nbsp;&nbsp;Acquisition and other-related costs | (0.3) |  |  | (0.3) |
| &nbsp;&nbsp;&nbsp;Loss on CTO resales | (26.5) |  | 26.5 |  |
| &nbsp;&nbsp;&nbsp;Gain (loss) on strategic investments | (4.8) |  | 4.8 |  |
| &nbsp;&nbsp;&nbsp;Inventory charges | (2.5) |  | 2.5 |  |
| &nbsp;&nbsp;Indirect costs allocated to Divestiture <sup>(1)</sup> |  | (6.2) |  | (6.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net income (loss)** | $(56.0) | $— | $79.2 | $23.2 |

---

_____________

(1) Includes indirect costs previously allocated to the Divestiture that are not eligible for discontinued operations accounting treatment.

------

**INGEVITY CORPORATION**

**Reconciliation of Recast Segment Operating Results (Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **2023 FY** | **2023 FY** | **2023 FY** | **2023 FY** |
| ***In millions*** | **As Previously Reported** | **Indirect costs allocated to Divestiture** <sup>(1)</sup> | **Discontinued Operations** | **Continuing Operations** |
| Performance Materials  | $586.0 | $— | $— | $586.0 |
| Performance Chemicals | 902.1 |  | (476.6) | 425.5 |
| Advanced Polymer Technologies | 204.0 |  |  | 204.0 |
| &nbsp;&nbsp;&nbsp;**Net sales** | $1692.1 | $— | $(476.6) | $1215.5 |
| Performance Materials | $286.6 | $— | $— | $286.6 |
| Performance Chemicals | 65.7 | 40.6 | (43.8) | 62.5 |
| Advanced Polymer Technologies | 44.5 |  |  | 44.5 |
| &nbsp;&nbsp;**Segment EBITDA**  | $396.8 | $40.6 | $(43.8) | $393.6 |
| &nbsp;&nbsp;Interest expense, net | (87.0) |  |  | (87.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;(Provision) benefit for income taxes | 4.7 |  | (28.9) | (24.2) |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | (122.8) |  | 25.4 | (97.4) |
| &nbsp;&nbsp;&nbsp;Restructuring and other income (charges), net | (170.2) |  | 116.8 | (53.4) |
| &nbsp;&nbsp;&nbsp;Acquisition and other-related costs | (4.5) |  |  | (4.5) |
| &nbsp;&nbsp;&nbsp;Inventory charges | (19.7) |  | 19.7 |  |
| &nbsp;&nbsp;&nbsp;Loss on CTO resales | (22.0) |  | 22.0 |  |
| &nbsp;&nbsp;&nbsp;Gain (loss) on strategic investments | 19.3 |  |  | 19.3 |
| &nbsp;&nbsp;Indirect costs allocated to Divestiture <sup>(1)</sup> |  | (40.6) |  | (40.6) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net income (loss)** | $(5.4) | $— | $111.2 | $105.8 |

---

_____________

(1) Includes indirect costs previously allocated to the Divestiture that are not eligible for discontinued operations accounting treatment.

------

**INGEVITY CORPORATION**

**Reconciliation of Recast Net Income (Loss) from Continuing Operations (GAAP) to Recast Adjusted Earnings (Loss) from Continuing Operations (Non-GAAP) and Recast Diluted Earnings (Loss) per Common Share from Continuing Operations (GAAP) to Recast Diluted Adjusted Earnings (Loss) per Common Share from Continuing Operations(Non-GAAP)**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **2023** | **2024** | **2024** | **2024** | **2024** | **2024** | **2025** | **2025** | **2025** |
| ***In millions, except per share data (unaudited)*** | **FY** | **Q1** | **Q2** | **Q3** | **Q4** | **FY** | **Q1** | **Q2** | **Q3** |
| **Net income (loss) from continuing operations (GAAP)** | $105.8 | $23.2 | $(211.6) | $47.5 | $19.5 | $(121.4) | $29.1 | $(141.4) | $40.8 |
| &nbsp;&nbsp;Restructuring and other (income) charges, net <sup>(1)</sup> | 53.4 | 1.3 | 3.7 | 3.3 | 9.8 | 18.1 | 1.9 | 7.2 | 1.0 |
| &nbsp;&nbsp;Goodwill impairment charge <sup>(2)</sup> |  |  | 306.6 |  |  | 306.6 |  | 183.8 |  |
| &nbsp;&nbsp;Acquisition and other-related costs <sup>(3)</sup> | 4.5 | 0.3 | (0.2) | (0.1) | 0.3 | 0.3 |  |  |  |
| &nbsp;&nbsp;Pension and postretirement settlement and curtailment charges (income) <sup>(4)</sup> |  |  |  |  | 0.2 | 0.2 |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;(Gain) loss on strategic investments <sup>(5)</sup> | (19.3) |  | (0.1) | 2.2 |  | 2.1 |  | 2.5 |  |
| &nbsp;&nbsp;Proxy contest charges <sup>(6)</sup> |  |  |  |  |  |  | 7.9 | 0.3 |  |
| &nbsp;&nbsp;Portfolio review expenses <sup>(7)</sup> |  |  |  |  |  |  |  |  | 1.1 |
| &nbsp;&nbsp;Tax effect on items above <sup>(8)</sup> | (9.1) | (0.3) | (72.9) | (1.0) | (4.4) | (78.6) | (2.3) | (48.4) | (0.5) |
| &nbsp;&nbsp;Certain discrete tax provision (benefit) <sup>(9)</sup> | (0.5) | 0.7 | 23.7 | (3.4) |  | 21.0 | 0.4 | 40.9 | 5.9 |
| **Adjusted earnings (loss) from continuing operations (Non-GAAP)** | $134.8 | $25.2 | $49.2 | $48.5 | $25.4 | $148.3 | $37.0 | $44.9 | $48.3 |
| **Diluted earnings (loss) per common share from continuing operations (GAAP)** | $2.88 | $0.64 | $(5.83) | $1.30 | $0.53 | $(3.34) | $0.79 | $(3.87) | $1.10 |
| &nbsp;&nbsp;Restructuring and other (income) charges, net <sup>(1)</sup> | 1.46 | 0.04 | 0.10 | 0.09 | 0.27 | 0.50 | 0.05 | 0.20 | 0.03 |
| &nbsp;&nbsp;Goodwill impairment charge <sup>(2)</sup> |  |  | 8.40 |  |  | 8.40 |  | 5.01 |  |
| &nbsp;&nbsp;Acquisition and other-related costs <sup>(3)</sup> | 0.12 | 0.01 | (0.01) |  | 0.01 | 0.01 |  |  |  |
| &nbsp;&nbsp;Pension and postretirement settlement and curtailment charges (income) <sup>(4)</sup> |  |  |  |  | 0.01 | 0.01 |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;(Gain) loss on strategic investments <sup>(5)</sup> | (0.52) |  |  | 0.06 |  | 0.06 |  | 0.07 |  |
| &nbsp;&nbsp;Proxy contest charges <sup>(6)</sup> |  |  |  |  |  |  | 0.21 | 0.01 |  |
| &nbsp;&nbsp;Portfolio review expenses <sup>(7)</sup> |  |  |  |  |  |  |  |  | 0.03 |
| &nbsp;&nbsp;Tax effect on items above <sup>(8)</sup> | (0.26) | (0.02) | (1.97) | (0.03) | (0.13) | (2.16) | (0.05) | (1.32) | (0.01) |
| &nbsp;&nbsp;Certain discrete tax provision (benefit) <sup>(9)</sup> | (0.01) | 0.02 | 0.66 | (0.09) |  | 0.58 | 0.01 | 1.12 | 0.16 |
| **Diluted adjusted earnings (loss) per common share from continuing operations (Non-GAAP)** | $3.67 | $0.69 | $1.35 | $1.33 | $0.69 | $4.06 | $1.01 | $1.22 | $1.31 |
| Weighted average common shares outstanding - Diluted | 36.7 | 36.4 | 36.5 | 36.5 | 36.6 | 36.5 | 36.7 | 36.7 | 37.0 |

---

------

_______________

(1) We regularly perform strategic reviews and assess the return on our operations, which sometimes results in a plan to restructure the business. These costs are excluded from adjusted earnings (loss) from continuing operations. For more information, refer to our previously filed Form 10-Q's and Form 10-K's filed with the Securities and Exchange Commission.

(2) During the second quarter of 2025, the company concluded that the carrying value of the Advanced Polymer Technologies reporting unit exceeded its fair value, resulting in a non-cash goodwill impairment charge. During the second quarter of 2024, the company concluded that the carrying value of the Performance Chemicals reporting unit exceeded its fair value, resulting in a non-cash goodwill impairment charge.

(3) Charges represent (income) losses incurred to complete and integrate acquisitions and other strategic investments. Charges may include the expensing of the inventory fair value step-up resulting from the application of purchase accounting for acquisitions and certain legal and professional fees associated with the completion of acquisitions and strategic investments.

(4) Our pension and postretirement settlement and curtailment charges (income) are related to the acceleration of prior service costs, as a result of a reduction in the number of participants within the Union Hourly defined benefit pension plan. These are excluded as we consider these costs to be outside our operational performance.

(5) We exclude gains and losses from strategic investments because we do not consider such gains or losses to be directly associated with our operational performance. We believe that the inclusion of such gains or losses, would impair the factors and trends affecting the historical financial performance of the Company. We continue to include undistributed earnings or loss, distributions, amortization or accretion of basis differences, and other-than-temporary impairments for equity method investments that we believe are directly attributable to the operational performance of such investments, in our consolidated results.

(6) Charges represent legal and other professional service fees as well as incremental proxy solicitation costs related to a proxy contest. These charges are excluded as we consider these costs to be outside our operational performance.

(7) Expenses represent professional service fees related to a review of the company's portfolio. These expenses are excluded as we consider these costs to be outside our operational performance.

(8) Income tax impact of non-GAAP adjustments is the summation of the calculated income tax charge related to each pre-tax non-GAAP adjustment. The non-GAAP adjustments relate primarily to adjustments in the United States. As such, the income tax effect is calculated using the statutory tax rates of 21% for the United States and approximately 2.5% for state and local taxes, applied to the non-GAAP adjustments.

(9) Represents certain discrete tax items such as excess tax benefits on stock compensation and impacts of legislative tax rate changes.

------

**INGEVITY CORPORATION**

**Reconciliations of Recast Net Income (Loss) (GAAP) to Recast Adjusted Earnings (Loss) (Non-GAAP) and Recast Diluted Earnings (Loss) per Common Share (GAAP) to Recast Diluted Adjusted Earnings (Loss) per Common Share (Non-GAAP)**

---

| | | | |
|:---|:---|:---|:---|
| | **2025 Q3** | **2025 Q3** | **2025 Q3** |
| ***In millions, except per share data (unaudited)*** | **Total Company** | **Discontinued Operations** | **Continuing Operations** |
| **Net income (loss) (GAAP)** | $43.5 | $2.7 | $40.8 |
| &nbsp;&nbsp;Restructuring and other (income) charges, net | 9.8 | 8.8 | 1.0 |
| &nbsp;&nbsp;&nbsp;Portfolio review expenses | 1.1 |  | 1.1 |
| &nbsp;&nbsp;Tax effect on items above | (2.5) | (2.0) | (0.5) |
| &nbsp;&nbsp;Certain discrete tax provision (benefit) | 4.4 | (1.5) | 5.9 |
| **Adjusted earnings (loss) (Non-GAAP)** | $56.3 | $8.0 | $48.3 |
| **Diluted earnings (loss) per common share (GAAP)** | $1.18 | $0.08 | $1.10 |
| &nbsp;&nbsp;&nbsp;Restructuring and other (income) charges, net | 0.26 | 0.23 | 0.03 |
| &nbsp;&nbsp;&nbsp;Portfolio review expenses | 0.03 |  | 0.03 |
| &nbsp;&nbsp;&nbsp;Tax effect on items above | (0.07) | (0.06) | (0.01) |
| &nbsp;&nbsp;&nbsp;Certain discrete tax provision (benefit) | 0.12 | (0.04) | 0.16 |
| **Diluted adjusted earnings (loss) per common share (Non-GAAP)** | $1.52 | $0.21 | $1.31 |
| Weighted average common shares outstanding - Diluted | 37.0 | 37.0 | 37.0 |

---

------

**INGEVITY CORPORATION**

**Reconciliations of Recast Net Income (Loss) (GAAP) to Recast Adjusted Earnings (Loss) (Non-GAAP) and Recast Diluted Earnings (Loss) per Common Share (GAAP) to Recast Diluted Adjusted Earnings (Loss) per Common Share (Non-GAAP)**

---

| | | | |
|:---|:---|:---|:---|
| | **2025 Q2** | **2025 Q2** | **2025 Q2** |
| ***In millions, except per share data (unaudited)*** | **As Previously Reported** | **Discontinued Operations** | **Continuing Operations** |
| **Net income (loss) (GAAP)** | $(146.5) | $(5.1) | $(141.4) |
| &nbsp;&nbsp;Restructuring and other (income) charges, net | 21.9 | 14.7 | 7.2 |
| &nbsp;&nbsp;&nbsp;Goodwill impairment charge | 183.8 |  | 183.8 |
| &nbsp;&nbsp;&nbsp;(Gain) loss on strategic investments | 2.5 |  | 2.5 |
| &nbsp;&nbsp;&nbsp;Proxy contest charges | 0.3 |  | 0.3 |
| &nbsp;&nbsp;Tax effect on items above | (51.8) | (3.4) | (48.4) |
| &nbsp;&nbsp;Certain discrete tax provision (benefit) | 40.9 |  | 40.9 |
| **Adjusted earnings (loss) (Non-GAAP)** | $51.1 | $6.2 | $44.9 |
| **Diluted earnings (loss) per common share (GAAP)** | $(4.02) | $(0.15) | $(3.87) |
| &nbsp;&nbsp;&nbsp;Restructuring and other (income) charges, net | 0.60 | 0.40 | 0.20 |
| &nbsp;&nbsp;&nbsp;Goodwill impairment charge | 5.03 | 0.02 | 5.01 |
| &nbsp;&nbsp;&nbsp;(Gain) loss on strategic investments | 0.07 |  | 0.07 |
| &nbsp;&nbsp;&nbsp;Proxy contest charges | 0.01 |  | 0.01 |
| &nbsp;&nbsp;&nbsp;Tax effect on items above | (1.42) | (0.10) | (1.32) |
| &nbsp;&nbsp;&nbsp;Certain discrete tax provision (benefit) | 1.12 |  | 1.12 |
| **Diluted adjusted earnings (loss) per common share (Non-GAAP)** | $1.39 | $0.17 | $1.22 |
| Weighted average common shares outstanding - Diluted <sup>(1)</sup> | 36.7 | 36.7 | 36.7 |
| ____________ | ____________ | ____________ | ____________ |
| (1) The weighted average number of common shares outstanding used in diluted adjusted earnings (loss) per share computation (Non-GAAP) differs from the weighted average number of common shares outstanding used in diluted earnings (loss) per share computations (GAAP) as we had a GAAP net loss for the respective period. | (1) The weighted average number of common shares outstanding used in diluted adjusted earnings (loss) per share computation (Non-GAAP) differs from the weighted average number of common shares outstanding used in diluted earnings (loss) per share computations (GAAP) as we had a GAAP net loss for the respective period. | (1) The weighted average number of common shares outstanding used in diluted adjusted earnings (loss) per share computation (Non-GAAP) differs from the weighted average number of common shares outstanding used in diluted earnings (loss) per share computations (GAAP) as we had a GAAP net loss for the respective period. | (1) The weighted average number of common shares outstanding used in diluted adjusted earnings (loss) per share computation (Non-GAAP) differs from the weighted average number of common shares outstanding used in diluted earnings (loss) per share computations (GAAP) as we had a GAAP net loss for the respective period. |

---

------

**INGEVITY CORPORATION**

**Reconciliations of Recast Net Income (Loss) (GAAP) to Recast Adjusted Earnings (Loss) (Non-GAAP) and Recast Diluted Earnings (Loss) per Common Share (GAAP) to Recast Diluted Adjusted Earnings (Loss) per Common Share (Non-GAAP)**

---

| | | | |
|:---|:---|:---|:---|
| | **2025 Q1** | **2025 Q1** | **2025 Q1** |
| ***In millions, except per share data (unaudited)*** | **As Previously Reported** | **Discontinued Operations** | **Continuing Operations** |
| **Net income (loss) (GAAP)** | $20.5 | $(8.6) | $29.1 |
| &nbsp;&nbsp;Restructuring and other (income) charges, net | 12.3 | 10.4 | 1.9 |
| &nbsp;&nbsp;&nbsp;Proxy contest charges | 7.9 |  | 7.9 |
| &nbsp;&nbsp;Tax effect on items above | (4.7) | (2.4) | (2.3) |
| &nbsp;&nbsp;Certain discrete tax provision (benefit) | 0.4 |  | 0.4 |
| **Adjusted earnings (loss) (Non-GAAP)** | $36.4 | $(0.6) | $37.0 |
| **Diluted earnings (loss) per common share (GAAP)** | $0.56 | $(0.23) | $0.79 |
| &nbsp;&nbsp;&nbsp;Restructuring and other (income) charges, net | 0.34 | 0.29 | 0.05 |
| &nbsp;&nbsp;&nbsp;Proxy contest charges | 0.21 |  | 0.21 |
| &nbsp;&nbsp;&nbsp;Tax effect on items above | (0.13) | (0.08) | (0.05) |
| &nbsp;&nbsp;&nbsp;Certain discrete tax provision (benefit) | 0.01 |  | 0.01 |
| **Diluted adjusted earnings (loss) per common share (Non-GAAP)** | $0.99 | $(0.02) | $1.01 |
| Weighted average common shares outstanding - Diluted | 36.7 | 36.7 | 36.7 |

---

------

**INGEVITY CORPORATION**

**Reconciliations of Recast Net Income (Loss) (GAAP) to Recast Adjusted Earnings (Loss) (Non-GAAP) and Recast Diluted Earnings (Loss) per Common Share (GAAP) to Recast Diluted Adjusted Earnings (Loss) per Common Share (Non-GAAP)**

---

| | | | |
|:---|:---|:---|:---|
| | **2024 FY** | **2024 FY** | **2024 FY** |
| ***In millions, except per share data (unaudited)*** | **As Previously Reported** | **Discontinued Operations** | **Continuing Operations** |
| **Net income (loss) (GAAP)** | $(430.3) | $(308.9) | $(121.4) |
| &nbsp;&nbsp;Restructuring and other (income) charges, net | 186.2 | 168.1 | 18.1 |
| &nbsp;&nbsp;&nbsp;Goodwill impairment charge | 349.1 | 42.5 | 306.6 |
| &nbsp;&nbsp;Acquisition and other-related costs | 0.3 |  | 0.3 |
| &nbsp;&nbsp;Loss on CTO resales | 52.7 | 52.7 |  |
| &nbsp;&nbsp;&nbsp;CTO supply contract termination charges | 100.0 | 100.0 |  |
| &nbsp;&nbsp;Pension and postretirement settlement and curtailment charges (income), net | 0.2 |  | 0.2 |
| &nbsp;&nbsp;&nbsp;(Gain) loss on strategic investments | 11.4 | 9.3 | 2.1 |
| &nbsp;&nbsp;Tax effect on items above | (165.7) | (87.1) | (78.6) |
| &nbsp;&nbsp;Certain discrete tax provision (benefit) | 24.4 | 3.4 | 21.0 |
| **Adjusted earnings (loss) (Non-GAAP)** | $128.3 | $(20.0) | $148.3 |
| **Diluted earnings (loss) per common share (GAAP)** | $(11.85) | $(8.51) | $(3.34) |
| &nbsp;&nbsp;&nbsp;Restructuring and other (income) charges, net | 5.12 | 4.62 | 0.50 |
| &nbsp;&nbsp;&nbsp;Goodwill impairment charge | 9.62 | 1.22 | 8.40 |
| &nbsp;&nbsp;&nbsp;Acquisition and other-related costs | 0.01 |  | 0.01 |
| &nbsp;&nbsp;&nbsp;Loss on CTO resales | 1.45 | 1.45 |  |
| &nbsp;&nbsp;&nbsp;CTO supply contract termination charges | 2.75 | 2.75 |  |
| &nbsp;&nbsp;Pension and postretirement settlement and curtailment charges (income), net | 0.01 |  | 0.01 |
| &nbsp;&nbsp;&nbsp;(Gain) loss on strategic investments | 0.31 | 0.25 | 0.06 |
| &nbsp;&nbsp;&nbsp;Tax effect on items above | (4.58) | (2.42) | (2.16) |
| &nbsp;&nbsp;&nbsp;Certain discrete tax provision (benefit) | 0.67 | 0.09 | 0.58 |
| **Diluted adjusted earnings (loss) per common share (Non-GAAP)** | $3.51 | $(0.55) | $4.06 |
| Weighted average common shares outstanding - Diluted | 36.5 | 36.5 | 36.5 |
| ____________ | ____________ | ____________ | ____________ |
| (1) The weighted average number of common shares outstanding used in diluted adjusted earnings (loss) per share computation (Non-GAAP) differs from the weighted average number of common shares outstanding used in diluted earnings (loss) per share computations (GAAP) as we had a GAAP net loss for the respective period. | (1) The weighted average number of common shares outstanding used in diluted adjusted earnings (loss) per share computation (Non-GAAP) differs from the weighted average number of common shares outstanding used in diluted earnings (loss) per share computations (GAAP) as we had a GAAP net loss for the respective period. | (1) The weighted average number of common shares outstanding used in diluted adjusted earnings (loss) per share computation (Non-GAAP) differs from the weighted average number of common shares outstanding used in diluted earnings (loss) per share computations (GAAP) as we had a GAAP net loss for the respective period. | (1) The weighted average number of common shares outstanding used in diluted adjusted earnings (loss) per share computation (Non-GAAP) differs from the weighted average number of common shares outstanding used in diluted earnings (loss) per share computations (GAAP) as we had a GAAP net loss for the respective period. |

---

------

**INGEVITY CORPORATION**

**Reconciliations of Recast Net Income (Loss) (GAAP) to Recast Adjusted Earnings (Loss) (Non-GAAP) and Recast Diluted Earnings (Loss) per Common Share (GAAP) to Recast Diluted Adjusted Earnings (Loss) per Common Share (Non-GAAP)**

---

| | | | |
|:---|:---|:---|:---|
| | **2024 Q4** | **2024 Q4** | **2024 Q4** |
| ***In millions, except per share data (unaudited)*** | **As Previously Reported** | **Discontinued Operations** | **Continuing Operations** |
| **Net income (loss) (GAAP)** | $16.6 | $(2.9) | $19.5 |
| &nbsp;&nbsp;Restructuring and other (income) charges, net | 23.4 | 13.6 | 9.8 |
| &nbsp;&nbsp;Acquisition and other-related costs | 0.3 |  | 0.3 |
| &nbsp;&nbsp;Loss on CTO resales | 1.9 | 1.9 |  |
| &nbsp;&nbsp;Pension and postretirement settlement and curtailment charges (income), net | 0.2 |  | 0.2 |
| &nbsp;&nbsp;Tax effect on items above | (7.7) | (3.3) | (4.4) |
| &nbsp;&nbsp;Certain discrete tax provision (benefit) |  |  |  |
| **Adjusted earnings (loss) (Non-GAAP)** | $34.7 | $9.3 | $25.4 |
| **Diluted earnings (loss) per common share (GAAP)** | $0.46 | $(0.07) | $0.53 |
| &nbsp;&nbsp;&nbsp;Restructuring and other (income) charges, net | 0.64 | 0.37 | 0.27 |
| &nbsp;&nbsp;&nbsp;Acquisition and other-related costs | 0.01 |  | 0.01 |
| &nbsp;&nbsp;&nbsp;Loss on CTO resales | 0.05 | 0.05 |  |
| &nbsp;&nbsp;Pension and postretirement settlement and curtailment charges (income), net | 0.01 |  | 0.01 |
| &nbsp;&nbsp;&nbsp;Tax effect on items above | (0.22) | (0.09) | (0.13) |
| &nbsp;&nbsp;&nbsp;Certain discrete tax provision (benefit) |  |  |  |
| **Diluted adjusted earnings (loss) per common share (Non-GAAP)** | $0.95 | $0.26 | $0.69 |
| Weighted average common shares outstanding - Diluted | 36.6 | 36.6 | 36.6 |

---

------

**INGEVITY CORPORATION**

**Reconciliations of Recast Net Income (Loss) (GAAP) to Recast Adjusted Earnings (Loss) (Non-GAAP) and Recast Diluted Earnings (Loss) per Common Share (GAAP) to Recast Diluted Adjusted Earnings (Loss) per Common Share (Non-GAAP)**

---

| | | | |
|:---|:---|:---|:---|
| | **2024 Q3** | **2024 Q3** | **2024 Q3** |
| ***In millions, except per share data (unaudited)*** | **As Previously Reported** | **Discontinued Operations** | **Continuing Operations** |
| **Net income (loss) (GAAP)** | $(107.2) | $(154.7) | $47.5 |
| &nbsp;&nbsp;Restructuring and other (income) charges, net | 86.9 | 83.6 | 3.3 |
| &nbsp;&nbsp;Acquisition and other-related costs | (0.1) |  | (0.1) |
| &nbsp;&nbsp;Loss on CTO resales | 0.8 | 0.8 |  |
| &nbsp;&nbsp;&nbsp;CTO supply contract termination charges | 100.0 | 100.0 |  |
| &nbsp;&nbsp;&nbsp;(Gain) loss on strategic investments | 6.7 | 4.5 | 2.2 |
| &nbsp;&nbsp;Tax effect on items above | (43.3) | (42.3) | (1.0) |
| &nbsp;&nbsp;Certain discrete tax provision (benefit) | (3.6) | (0.2) | (3.4) |
| **Adjusted earnings (loss) (Non-GAAP)** | $40.2 | $(8.3) | $48.5 |
| **Diluted earnings (loss) per common share (GAAP)** | $(2.95) | $(4.24) | $1.30 |
| &nbsp;&nbsp;&nbsp;Restructuring and other (income) charges, net | 2.39 | 2.30 | 0.09 |
| &nbsp;&nbsp;&nbsp;Acquisition and other-related costs |  |  |  |
| &nbsp;&nbsp;&nbsp;Loss on CTO resales | 0.02 | 0.02 |  |
| &nbsp;&nbsp;&nbsp;CTO supply contract termination charges | 2.75 | 2.75 |  |
| &nbsp;&nbsp;&nbsp;(Gain) loss on strategic investments | 0.18 | 0.12 | 0.06 |
| &nbsp;&nbsp;&nbsp;Tax effect on items above | (1.19) | (1.17) | (0.03) |
| &nbsp;&nbsp;&nbsp;Certain discrete tax provision (benefit) | (0.10) | (0.01) | (0.09) |
| **Diluted adjusted earnings (loss) per common share (Non-GAAP)** | $1.10 | $(0.23) | $1.33 |
| Weighted average common shares outstanding - Diluted | 36.5 | 36.5 | 36.5 |

---

------

**INGEVITY CORPORATION**

**Reconciliations of Recast Net Income (Loss) (GAAP) to Recast Adjusted Earnings (Loss) (Non-GAAP) and Recast Diluted Earnings (Loss) per Common Share (GAAP) to Recast Diluted Adjusted Earnings (Loss) per Common Share (Non-GAAP)**

---

| | | | |
|:---|:---|:---|:---|
| | **2024 Q2** | **2024 Q2** | **2024 Q2** |
| ***In millions, except per share data (unaudited)*** | **As Previously Reported** | **Discontinued Operations** | **Continuing Operations** |
| **Net income (loss) (GAAP)** | $(283.7) | $(72.1) | $(211.6) |
| &nbsp;&nbsp;Restructuring and other (income) charges, net | 13.1 | 9.4 | 3.7 |
| &nbsp;&nbsp;&nbsp;Goodwill impairment charge | 349.1 | 42.5 | 306.6 |
| &nbsp;&nbsp;Acquisition and other-related costs | (0.2) |  | (0.2) |
| &nbsp;&nbsp;Loss on CTO resales | 23.5 | 23.5 |  |
| &nbsp;&nbsp;&nbsp;(Gain) loss on strategic investments | (0.1) |  | (0.1) |
| &nbsp;&nbsp;Tax effect on items above | (92.0) | (19.1) | (72.9) |
| &nbsp;&nbsp;Certain discrete tax provision (benefit) | 27.1 | 3.4 | 23.7 |
| **Adjusted earnings (loss) (Non-GAAP)** | $36.8 | $(12.4) | $49.2 |
| **Diluted earnings (loss) per common share (GAAP)** | $(7.81) | $(1.98) | $(5.83) |
| &nbsp;&nbsp;&nbsp;Restructuring and other (income) charges, net | 0.36 | 0.26 | 0.10 |
| &nbsp;&nbsp;&nbsp;Goodwill impairment charge | 9.62 | 1.22 | 8.40 |
| &nbsp;&nbsp;&nbsp;Acquisition and other-related costs | (0.01) |  | (0.01) |
| &nbsp;&nbsp;&nbsp;Loss on CTO resales | 0.65 | 0.65 |  |
| &nbsp;&nbsp;&nbsp;(Gain) loss on strategic investments |  |  |  |
| &nbsp;&nbsp;&nbsp;Tax effect on items above | (2.55) | (0.58) | (1.97) |
| &nbsp;&nbsp;&nbsp;Certain discrete tax provision (benefit) | 0.75 | 0.09 | 0.66 |
| **Diluted adjusted earnings (loss) per common share (Non-GAAP)** | $1.01 | $(0.34) | $1.35 |
| Weighted average common shares outstanding - Diluted | 36.5 | 36.5 | 36.5 |
| ____________ | ____________ | ____________ | ____________ |
| (1) The weighted average number of common shares outstanding used in diluted adjusted earnings (loss) per share computation (Non-GAAP) differs from the weighted average number of common shares outstanding used in diluted earnings (loss) per share computations (GAAP) as we had a GAAP net loss for the respective period. | (1) The weighted average number of common shares outstanding used in diluted adjusted earnings (loss) per share computation (Non-GAAP) differs from the weighted average number of common shares outstanding used in diluted earnings (loss) per share computations (GAAP) as we had a GAAP net loss for the respective period. | (1) The weighted average number of common shares outstanding used in diluted adjusted earnings (loss) per share computation (Non-GAAP) differs from the weighted average number of common shares outstanding used in diluted earnings (loss) per share computations (GAAP) as we had a GAAP net loss for the respective period. | (1) The weighted average number of common shares outstanding used in diluted adjusted earnings (loss) per share computation (Non-GAAP) differs from the weighted average number of common shares outstanding used in diluted earnings (loss) per share computations (GAAP) as we had a GAAP net loss for the respective period. |

---

------

**INGEVITY CORPORATION**

**Reconciliations of Recast Net Income (Loss) (GAAP) to Recast Adjusted Earnings (Loss) (Non-GAAP) and Recast Diluted Earnings (Loss) per Common Share (GAAP) to Recast Diluted Adjusted Earnings (Loss) per Common Share (Non-GAAP)**

---

| | | | |
|:---|:---|:---|:---|
| | **2024 Q1** | **2024 Q1** | **2024 Q1** |
| ***In millions, except per share data (unaudited)*** | **As Previously Reported** | **Discontinued Operations** | **Continuing Operations** |
| **Net income (loss) (GAAP)** | $(56.0) | $(79.2) | $23.2 |
| &nbsp;&nbsp;Restructuring and other (income) charges, net | 62.8 | 61.5 | 1.3 |
| &nbsp;&nbsp;Acquisition and other-related costs | 0.3 |  | 0.3 |
| &nbsp;&nbsp;Loss on CTO resales | 26.5 | 26.5 |  |
| &nbsp;&nbsp;&nbsp;(Gain) loss on strategic investments | 4.8 | 4.8 |  |
| &nbsp;&nbsp;Tax effect on items above | (22.1) | (21.8) | (0.3) |
| &nbsp;&nbsp;Certain discrete tax provision (benefit) | 0.9 | 0.2 | 0.7 |
| **Adjusted earnings (loss) (Non-GAAP)** | $17.2 | $(8.0) | $25.2 |
| **Diluted earnings (loss) per common share (GAAP)** | $(1.54) | $(2.18) | $0.64 |
| &nbsp;&nbsp;&nbsp;Restructuring and other (income) charges, net | 1.73 | 1.69 | 0.04 |
| &nbsp;&nbsp;&nbsp;Acquisition and other-related costs | 0.01 |  | 0.01 |
| &nbsp;&nbsp;&nbsp;Loss on CTO resales | 0.73 | 0.73 |  |
| &nbsp;&nbsp;&nbsp;(Gain) loss on strategic investments | 0.13 | 0.13 |  |
| &nbsp;&nbsp;&nbsp;Tax effect on items above | (0.61) | (0.59) | (0.02) |
| &nbsp;&nbsp;&nbsp;Certain discrete tax provision (benefit) | 0.02 |  | 0.02 |
| **Diluted adjusted earnings (loss) per common share (Non-GAAP)** | $0.47 | $(0.22) | $0.69 |
| Weighted average common shares outstanding - Diluted | 36.4 | 36.4 | 36.4 |

---

------

**INGEVITY CORPORATION**

**Reconciliations of Recast Net Income (Loss) (GAAP) to Recast Adjusted Earnings (Loss) (Non-GAAP) and Recast Diluted Earnings (Loss) per Common Share (GAAP) to Recast Diluted Adjusted Earnings (Loss) per Common Share (Non-GAAP)**

---

| | | | |
|:---|:---|:---|:---|
| | **2023 FY** | **2023 FY** | **2023 FY** |
| ***In millions, except per share data (unaudited)*** | **As Previously Reported** | **Discontinued Operations** | **Continuing Operations** |
| **Net income (loss) (GAAP)** | $(5.4) | $(111.2) | $105.8 |
| &nbsp;&nbsp;Restructuring and other (income) charges, net | 170.2 | 116.8 | 53.4 |
| &nbsp;&nbsp;Acquisition and other-related costs | 4.5 |  | 4.5 |
| &nbsp;&nbsp;Loss on CTO resales | 22.0 | 22.0 |  |
| &nbsp;&nbsp;&nbsp;(Gain) loss on strategic investments | (19.3) |  | (19.3) |
| &nbsp;&nbsp;Tax effect on items above | (41.8) | (32.7) | (9.1) |
| &nbsp;&nbsp;Certain discrete tax provision (benefit) | (0.6) | (0.1) | (0.5) |
| **Adjusted earnings (loss) (Non-GAAP)** | $129.6 | $(5.2) | $134.8 |
| **Diluted earnings (loss) per common share (GAAP)** | $(0.15) | $(3.03) | $2.88 |
| &nbsp;&nbsp;&nbsp;Restructuring and other (income) charges, net | 4.64 | 3.18 | 1.46 |
| &nbsp;&nbsp;&nbsp;Acquisition and other-related costs | 0.12 |  | 0.12 |
| &nbsp;&nbsp;&nbsp;Loss on CTO resales | 0.60 | 0.60 |  |
| &nbsp;&nbsp;&nbsp;(Gain) loss on strategic investments | (0.52) |  | (0.52) |
| &nbsp;&nbsp;&nbsp;Tax effect on items above | (1.14) | (0.88) | (0.26) |
| &nbsp;&nbsp;&nbsp;Certain discrete tax provision (benefit) | (0.02) | (0.01) | (0.01) |
| **Diluted adjusted earnings (loss) per common share (Non-GAAP)** | $3.53 | $(0.14) | $3.67 |
| Weighted average common shares outstanding - Diluted | 36.7 | 36.7 | 36.7 |

---

------

**INGEVITY CORPORATION**

**Reconciliation of Recast Net Income (Loss) from Continuing Operations (GAAP) to Recast Adjusted EBITDA (Non-GAAP)**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **2023** | **2024** | **2024** | **2024** | **2024** | **2024** | **2025** | **2025** | **2025** |
| ***In millions, except percentages (unaudited)*** | **FY** | **Q1** | **Q2** | **Q3** | **Q4** | **FY** | **Q1** | **Q2** | **Q3** |
| **Net income (loss) from continuing operations (GAAP)** | $105.8 | $23.2 | $(211.6) | $47.5 | $19.5 | $(121.4) | $29.1 | $(141.4) | $40.8 |
| &nbsp;&nbsp;&nbsp;Provision (benefit) for income taxes | 24.2 | 7.7 | (37.9) | 6.5 | 4.6 | (19.1) | 8.5 | 4.8 | 21.4 |
| &nbsp;&nbsp;&nbsp;Interest expense, net | 87.0 | 22.3 | 23.2 | 23.8 | 20.8 | 90.1 | 19.4 | 18.6 | 18.4 |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 97.4 | 24.4 | 25.3 | 25.2 | 24.7 | 99.6 | 24.5 | 25.2 | 27.7 |
| &nbsp;&nbsp;Restructuring and other (income) charges, net | 53.4 | 1.3 | 3.7 | 3.3 | 9.8 | 18.1 | 1.9 | 7.2 | 1.0 |
| &nbsp;&nbsp;Goodwill impairment charge  |  |  | 306.6 |  |  | 306.6 |  | 183.8 |  |
| &nbsp;&nbsp;&nbsp;Acquisition and other-related (income) costs | 4.5 | 0.3 | (0.2) | (0.1) | 0.3 | 0.3 |  |  |  |
| &nbsp;&nbsp;&nbsp;Pension and postretirement settlement and curtailment (charges) income, net |  |  |  |  | 0.2 | 0.2 |  |  |  |
| &nbsp;&nbsp;&nbsp;(Gain) loss on strategic investments | (19.3) |  | (0.1) | 2.2 |  | 2.1 |  | 2.5 |  |
| &nbsp;&nbsp;&nbsp;Proxy contest charges |  |  |  |  |  |  | 7.9 | 0.3 |  |
| &nbsp;&nbsp;&nbsp;Portfolio review expenses |  |  |  |  |  |  |  |  | 1.1 |
| **Adjusted EBITDA from continuing operations (Non-GAAP)** | $353.0 | $79.2 | $109.0 | $108.4 | $79.9 | $376.5 | $91.3 | $101.0 | $110.4 |
| Net sales from continuing operations | $1215.5 | $255.2 | $347.7 | $333.8 | $263.4 | $1200.1 | $247.9 | $331.5 | $333.1 |
| Net income (loss) from continuing operations margin as a percentage of Net Sales from continuing operations | 8.7% | 9.1% | (60.9)% | 14.2% | 7.4% | (10.1)% | 11.7% | (42.7)% | 12.2% |
| Adjusted EBITDA margin from continuing operations | 29.0% | 31.0% | 31.3% | 32.5% | 30.3% | 31.4% | 36.8% | 30.5% | 33.1% |

---

------

**INGEVITY CORPORATION**

**Net Debt Ratio (Non-GAAP)**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **2023** | **2024** | **2024** | **2024** | **2024** | **2025** | **2025** | **2025** |
| ***In millions, except ratios (unaudited)*** | **Q4** | **Q1** | **Q2** | **Q3** | **Q4** | **Q1** | **Q2** | **Q3** |
| &nbsp;&nbsp;&nbsp;&nbsp;Notes payable and current maturities of long-term debt | $84.4 | $84.7 | $103.0 | $100.7 | $61.3 | $60.4 | $94.7 | $102.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term debt including finance lease obligations | 1382.8 | 1408.7 | 1401.0 | 1397.6 | 1339.7 | 1332.6 | 1235.6 | 1158.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Debt issuance costs | 5.3 | 5.0 | 4.8 | 4.5 | 4.2 | 4.0 | 3.7 | 3.4 |
| &nbsp;&nbsp;&nbsp;Total Debt | 1472.5 | 1498.4 | 1508.8 | 1502.8 | 1405.2 | 1397.0 | 1334.0 | 1263.9 |
| &nbsp;&nbsp;&nbsp;Less: |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents <sup>(1)</sup> | 96.1 | 88.7 | 107.6 | 135.7 | 68.2 | 71.7 | 77.0 | 83.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted investment <sup>(2)</sup> | 79.3 | 79.9 | 80.6 | 81.3 | 81.8 | 82.5 | 83.2 | 83.9 |
| Net Debt | $1297.1 | $1329.8 | $1320.6 | $1285.8 | $1255.2 | $1242.8 | $1173.8 | $1096.5 |
| **Net Debt Ratio (Non GAAP)** |  |  |  |  |  |  |  |  |
| Total Adjusted EBITDA<sup>(3)</sup> - last twelve months | $377.1 | $347.6 | $328.2 | $324.2 | $362.7 | $379.6 | $388.3 | $403.1 |
| &nbsp;&nbsp;&nbsp;Net debt ratio (Non GAAP) | 3.4x | 3.8x | 4.0x | 4.0x | 3.5x | 3.3x | 3.0x | 2.7x |
| _______________ |  |  |  |  |  |  |  |  |
| (1) Includes Restricted Cash related to the New Market Tax Credit arrangement. | (1) Includes Restricted Cash related to the New Market Tax Credit arrangement. | (1) Includes Restricted Cash related to the New Market Tax Credit arrangement. | (1) Includes Restricted Cash related to the New Market Tax Credit arrangement. | (1) Includes Restricted Cash related to the New Market Tax Credit arrangement. | (1) Includes Restricted Cash related to the New Market Tax Credit arrangement. | (1) Includes Restricted Cash related to the New Market Tax Credit arrangement. | (1) Includes Restricted Cash related to the New Market Tax Credit arrangement. | (1) Includes Restricted Cash related to the New Market Tax Credit arrangement. |
| (2) Our restricted investment is a trust managed in order to secure repayment of the finance lease obligation associated with Performance Materials' Wickliffe, Kentucky, manufacturing site at maturity. The trust, presented as Restricted investment on our condensed consolidated balance sheets, originally purchased long-term bonds that mature through 2026. The principal received at maturity of the bonds, along with interest income that is reinvested in the trust, are expected to be equal to or more than the $80.0 million finance lease obligation that is due in 2027. Excludes allowance for credit losses on held-to-maturity debt securities. | (2) Our restricted investment is a trust managed in order to secure repayment of the finance lease obligation associated with Performance Materials' Wickliffe, Kentucky, manufacturing site at maturity. The trust, presented as Restricted investment on our condensed consolidated balance sheets, originally purchased long-term bonds that mature through 2026. The principal received at maturity of the bonds, along with interest income that is reinvested in the trust, are expected to be equal to or more than the $80.0 million finance lease obligation that is due in 2027. Excludes allowance for credit losses on held-to-maturity debt securities. | (2) Our restricted investment is a trust managed in order to secure repayment of the finance lease obligation associated with Performance Materials' Wickliffe, Kentucky, manufacturing site at maturity. The trust, presented as Restricted investment on our condensed consolidated balance sheets, originally purchased long-term bonds that mature through 2026. The principal received at maturity of the bonds, along with interest income that is reinvested in the trust, are expected to be equal to or more than the $80.0 million finance lease obligation that is due in 2027. Excludes allowance for credit losses on held-to-maturity debt securities. | (2) Our restricted investment is a trust managed in order to secure repayment of the finance lease obligation associated with Performance Materials' Wickliffe, Kentucky, manufacturing site at maturity. The trust, presented as Restricted investment on our condensed consolidated balance sheets, originally purchased long-term bonds that mature through 2026. The principal received at maturity of the bonds, along with interest income that is reinvested in the trust, are expected to be equal to or more than the $80.0 million finance lease obligation that is due in 2027. Excludes allowance for credit losses on held-to-maturity debt securities. | (2) Our restricted investment is a trust managed in order to secure repayment of the finance lease obligation associated with Performance Materials' Wickliffe, Kentucky, manufacturing site at maturity. The trust, presented as Restricted investment on our condensed consolidated balance sheets, originally purchased long-term bonds that mature through 2026. The principal received at maturity of the bonds, along with interest income that is reinvested in the trust, are expected to be equal to or more than the $80.0 million finance lease obligation that is due in 2027. Excludes allowance for credit losses on held-to-maturity debt securities. | (2) Our restricted investment is a trust managed in order to secure repayment of the finance lease obligation associated with Performance Materials' Wickliffe, Kentucky, manufacturing site at maturity. The trust, presented as Restricted investment on our condensed consolidated balance sheets, originally purchased long-term bonds that mature through 2026. The principal received at maturity of the bonds, along with interest income that is reinvested in the trust, are expected to be equal to or more than the $80.0 million finance lease obligation that is due in 2027. Excludes allowance for credit losses on held-to-maturity debt securities. | (2) Our restricted investment is a trust managed in order to secure repayment of the finance lease obligation associated with Performance Materials' Wickliffe, Kentucky, manufacturing site at maturity. The trust, presented as Restricted investment on our condensed consolidated balance sheets, originally purchased long-term bonds that mature through 2026. The principal received at maturity of the bonds, along with interest income that is reinvested in the trust, are expected to be equal to or more than the $80.0 million finance lease obligation that is due in 2027. Excludes allowance for credit losses on held-to-maturity debt securities. | (2) Our restricted investment is a trust managed in order to secure repayment of the finance lease obligation associated with Performance Materials' Wickliffe, Kentucky, manufacturing site at maturity. The trust, presented as Restricted investment on our condensed consolidated balance sheets, originally purchased long-term bonds that mature through 2026. The principal received at maturity of the bonds, along with interest income that is reinvested in the trust, are expected to be equal to or more than the $80.0 million finance lease obligation that is due in 2027. Excludes allowance for credit losses on held-to-maturity debt securities. | (2) Our restricted investment is a trust managed in order to secure repayment of the finance lease obligation associated with Performance Materials' Wickliffe, Kentucky, manufacturing site at maturity. The trust, presented as Restricted investment on our condensed consolidated balance sheets, originally purchased long-term bonds that mature through 2026. The principal received at maturity of the bonds, along with interest income that is reinvested in the trust, are expected to be equal to or more than the $80.0 million finance lease obligation that is due in 2027. Excludes allowance for credit losses on held-to-maturity debt securities. |
| (3) Total Adjusted EBITDA is defined as Adjusted EBITDA from continuing operations and Adjusted EBITDA from discontinued operations. | (3) Total Adjusted EBITDA is defined as Adjusted EBITDA from continuing operations and Adjusted EBITDA from discontinued operations. | (3) Total Adjusted EBITDA is defined as Adjusted EBITDA from continuing operations and Adjusted EBITDA from discontinued operations. | (3) Total Adjusted EBITDA is defined as Adjusted EBITDA from continuing operations and Adjusted EBITDA from discontinued operations. | (3) Total Adjusted EBITDA is defined as Adjusted EBITDA from continuing operations and Adjusted EBITDA from discontinued operations. | (3) Total Adjusted EBITDA is defined as Adjusted EBITDA from continuing operations and Adjusted EBITDA from discontinued operations. | (3) Total Adjusted EBITDA is defined as Adjusted EBITDA from continuing operations and Adjusted EBITDA from discontinued operations. | (3) Total Adjusted EBITDA is defined as Adjusted EBITDA from continuing operations and Adjusted EBITDA from discontinued operations. | (3) Total Adjusted EBITDA is defined as Adjusted EBITDA from continuing operations and Adjusted EBITDA from discontinued operations. |

---